0001144204-16-100409.txt : 20160510 0001144204-16-100409.hdr.sgml : 20160510 20160510160222 ACCESSION NUMBER: 0001144204-16-100409 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160510 DATE AS OF CHANGE: 20160510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Celator Pharmaceuticals Inc CENTRAL INDEX KEY: 0001327467 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36179 FILM NUMBER: 161635664 BUSINESS ADDRESS: STREET 1: 303B COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 243-0123 MAIL ADDRESS: STREET 1: 303B COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 10-Q 1 v437910_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2016

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-54852

CELATOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2680869
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

200 PrincetonSouth Corporate Center Suite 180 Ewing, New Jersey		08628
(Address of principal executive offices)		(Zip Code)

(609)-243-0123

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller Reporting Company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares outstanding of the registrant’s common stock, $0.001 par value, as of May 6, 2016 was 42,470,256.

CELATOR PHARMACEUTICALS, INC.

TABLE OF CONTENTS

		Page
Part I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	1
	Consolidated Balance Sheets as March 31, 2016 and December 31, 2015	1
	Consolidated Statements of Loss for the three months ended March 31, 2016 and 2015	2
	Consolidated Statement of Stockholders’ Equity for the three months ended March 31, 2016	3
	Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015	4
	Notes to Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.	Controls and Procedures	18

Part II.	OTHER INFORMATION

Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 6.	Exhibits	19
Signature		19
Certifications

Part I. Financial Information

Item 1. Financial Statements

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Balance Sheets

(Unaudited)

	March 31, 2016			December 31, 2015
Assets
Current assets:
Cash and cash equivalents	$	67,541,467		$	23,253,328
Restricted cash		150,921			149,017
Other receivables		116,859			74,244
Prepaid expenses and deposits		329,800			421,491
Other current assets		407,043			414,904
Total current assets		68,546,090			24,312,984
Property and equipment, net		816,438			861,490
Other assets		43,024			43,998
Total assets	$	69,405,552		$	25,218,472

Liabilities
Current liabilities:
Current portion of debt	$	436,690		$	5,378,134
Accounts payable		394,369			778,360
Accrued liabilities		2,081,544			2,377,713
Current portion of deferred revenue		-			45,249
Total current liabilities		2,912,603			8,579,456
Other liabilities		1,024,177			1,026,993
Loans payable		12,837,810			9,081,110
Total liabilities		16,774,590			18,687,559

Stockholders' equity
Preferred stock
Authorized 20,000,000 shares, par value $0.001		-			-
Common stock
Authorized 200,000,000 shares, par value $0.001
Issued and outstanding 41,222,270 and 34,944,150 shares as of March 31, 2016 and December 31, 2015, respectively		41,222			34,944
Warrants		1,083,193			1,083,193
Additional paid-in capital		226,856,737			175,229,643
Accumulated other comprehensive loss		(1,133,266	)		(1,133,266	)
Accumulated deficit		(174,216,924	)		(168,683,601	)
Total stockholders' equity		52,630,962			6,530,913
Total liabilities and stockholders' equity	$	69,405,552		$	25,218,472

See accompanying notes to consolidated financial statements.

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Statements of Loss

(Unaudited)

	Three months ended
	March 31
	2016			2015
Expenses
Research and development	$	2,689,189		$	2,708,011
Leukemia & Lymphoma Society funding		(145,249	)		(135,747	)
General and administrative		2,468,648			1,761,449
Amortization and depreciation		48,347			48,928
Operating loss		(5,060,935	)		(4,382,641	)
Other income (expenses)
Foreign exchange gain (loss)		(15,984	)		9,639
Interest and miscellaneous income		2,329			3,141
Interest expense		(458,733	)		(341,122	)
Net loss	$	(5,533,323	)	$	(4,710,983	)

Net loss per share
Basic and diluted	$	(0.16	)	$	(0.14	)

Weighted average of common shares outstanding
Basic and diluted		35,400,496			33,704,889

See accompanying notes to consolidated financial statements.

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Statement of Stockholders’ Equity

For the Three Months Ended March 31, 2016

(Unaudited)

	Common Stock						Additional Paid-In		Accumulated Other						Stockholders’
	Number		Amount		Warrants		Capital		Comprehensive Loss			Accumulated Deficit			Equity

Balance at December 31, 2015		34,944,150	$	34,944	$	1,083,193	$	175,229,643	$	(1,133,266	)	$	(168,683,601	)	$	6,530,913
Issuance of shares from exercise of stock options and warrants		324,220		324		-		295,316		-			-			295,640
Issued for cash, net of stock issuance costs		5,953,900		5,954		-		50,390,446		-			-			50,396,400
Stock-based compensation		-		-		-		576,070		-			-			576,070
Stock options granted in payment of accrued bonuses		-		-		-		365,262		-			-			365,262
Net loss for the period		-		-		-		-		-			(5,533,323	)		(5,533,323	)
Balance at March 31, 2016		41,222,270	$	41,222	$	1,083,193	$	226,856,737	$	(1,133,266	)	$	(174,216,924	)	$	52,630,962

See accompanying notes to consolidated financial statements.

Celator Pharmaceuticals, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

	Three months ended
	March 31
	2016			2015
Operating activities
Net loss	$	(5,533,323	)	$	(4,710,983	)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation		48,347			48,928
Non-cash stock-based compensation expense		576,070			359,200
Non-cash financing costs		112,117			94,664
Changes in operating assets and liabilities
Other receivables		(42,362	)		(4,864	)
Prepaid expenses and deposits		94,826			79,617
Restricted cash		(6	)		(8	)
Other current assets		7,861			16,266
Other assets		1,012			-
Accounts payable		(385,118	)		46,113
Accrued liabilities		62,979			(285,171	)
Deferred rent liability		(2,816	)		(2,218	)
Deferred revenue		(45,249	)		(135,746	)
Cash used in operating activities		(5,105,662	)		(4,494,202	)

Investing activities
Purchase of property and equipment		(3,295	)		(17,938	)
Cash used in investing activities		(3,295	)		(17,938	)

Financing activities
Proceeds from issuance of common stock and stock options and warrants exercised		51,105,723			-
Payment of share issuance costs		(413,357	)		-
Proceeds from loans payable		-			5,000,000
Repayments of loans payable		(1,296,861	)		-
Cash provided by financing activities		49,395,505			5,000,000

Effect of foreign exchange rate changes		1,591			(3,825	)

Net change in cash		44,288,139			484,035
Cash and cash equivalents, beginning of period		23,253,328			32,413,777
Cash and cash equivalents, end of period	$	67,541,467		$	32,897,812

Supplemental disclosure of cash flow information
Interest paid	$	356,166		$	243,750
Stock options granted in payment of accrued bonuses	$	365,262			-
Common stock issued in payment of accrued bonuses		-		$	168,843
Warrants issued in connection with debt issuance costs		-		$	76,897

See accompanying notes to consolidated financial statements

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Nature of Business and Liquidity

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Our proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor. Our lead product is VYXEOS^TM, a nano-scale liposomal formulation of cytarabine:daunorubicin, completed a Phase 3 clinical trial for the treatment of acute myeloid leukemia (AML). On March 14, 2016 we reported positive results from our Phase 3 study of VYXEOS in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, we have advanced the CombiPlex platform and broadened its application to include molecularly targeted therapies.

The Company has incurred recurring losses and negative cash flows from operations since inception. As of March 31, 2016, the Company had an accumulated deficit of $174.2 million. The Company expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. Management believes that the cash and cash equivalents of $67.5 million at March 31, 2016 will be sufficient to meet estimated working capital requirements and fund operations into 2018.

The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Summary of Significant Accounting Policies

The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.

In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Basis of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.

Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

New Accounting Pronouncements Adopted: During the period, the Company adopted Financial Accounting Standards Board (“FASB”) guidance originally issued in April 2015 which requires that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related liability, rather than as a deferred charge. The guidance was effective retroactively for financial statements covering fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The following table summarizes the cumulative effect of the change on total assets, total liabilities and stockholders’ equity in the statement of financial position as of the beginning of the period presented. The adoption of the guidance did not have any effect on loss from operations, and loss per share amounts for the current period and any prior periods.

	As Reported		Deferred Financing Costs			Adjusted
	December 31, 2015		Reclassification			December 31, 2015
Assets
Other assets	$	460,710	$	(416,712	)	$	43,998
Total assets	$	25,635,184	$	(416,712	)	$	25,218,472

Loans payable	$	9,497,822	$	(416,712	)	$	9,081,110
Total liabilities		19,104,271		(416,712	)		18,687,559

Total liabilities and stockholders' equity	$	25,635,184	$	(416,712	)	$	25,218,472

All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements.

New Accounting Pronouncements Not Yet Effective: In February 2016, the FASB issued comprehensive new guidance about leases. Under the new guidance, most leases will be recognized on an entity’s balance sheet as liabilities with corresponding right-of-use assets. The new guidance is effective for interim and annual period in fiscal years beginning after December 15, 2018, with early adoption permitted. The standard must be adopted using a modified retrospective approach. We have not yet evaluated the impact of this new pronouncement.

In November 2015, the FASB issued guidance which requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The guidance is effective for public business entities for interim and annual periods in fiscal years beginning after December 15, 2016. This guidance is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

In August 2014, the FASB issued guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

Fair Value Measurements

Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. The Company believes that the current carrying amount of its long-term debt approximates fair value because interest rate on this instrument is similar to rates that the Company would be able to receive for similar instruments of comparable maturity.

FASB Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.

The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:

	Fair Value		(Level 1)		(Level 2)		(Level 3)
March 31, 2016
Assets:
Money Market Fund	$	17,194,140	$	17,194,140	$	-	$	-

December 31, 2015
Assets:
Money Market Fund	$	22,162,678	$	22,162,678	$	-	$	-

Other Current Assets

Other current assets as of March 31, 2016 and December 31, 2015, consist of the following:

		March 31, 2016				December 31, 2015
Clinical trial materials		$	407,043			$	414,904

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Property and Equipment

Property and equipment as of March 31, 2016 and December 31, 2015, including assets held under capital lease, consists of the following:

	March 31, 2016			December 31, 2015
Computer and equipment	$	118,935		$	117,135
Furniture and office equipment		73,863			73,863
Laboratory equipment		1,754,608			1,754,608
Capital lease equipment		155,524			155,524
Leaseholds		56,227			54,732
		2,159,157			2,155,862
Less: Accumulated depreciation		(1,342,719	)		(1,294,372	)
	$	816,438		$	861,490

During the three months ended March 31, 2016 and March 31, 2015, depreciation and amortization expense was $48,347 and $48,928 respectively.

Accrued Liabilities

Accrued liabilities as of March 31, 2016 and December 31, 2015 consist of the following:

	March 31, 2016		December 31, 2015
Accrued clinical trial expenses	$	1,042,050	$	1,029,488
Accrued bonuses		254,425		723,039
Accrued salaries and vacation		194,438		202,059
Accrued drug manufacturing expenses		267,802		174,376
Interest payable		114,319		123,867
Accrued other		208,510		124,884
	$	2,081,544	$	2,377,713

Other Liabilities

Other non-current liabilities as of March 31, 2016 and December 31, 2015 consist of the following:

	March 31, 2016		December 31, 2015
Non-current income tax liability	$	991,654	$	991,654
Deferred rent		32,523		35,339
	$	1,024,177	$	1,026,993

In 2015, the Company completed a U.S. Federal and State of New Jersey Research and Development and U.S. Federal Orphan Drug tax credits analysis related to the years ended December 31, 2008 through 2014. The Company will claim the U.S. Federal Research and Development and Orphan Drug tax credits in the future on U.S. Federal tax returns. As a result, the Company will file amended New Jersey tax returns to report an income tax liability and interest which the Company recorded in 2015 as a non-current liability of $991,654 disclosed above.

Loans Payable

On May 9, 2014, the Company entered into a term loan agreement for $15 million with Hercules Technology Capital Growth (“Hercules”). The first $10 million of the term loan was funded at closing. On March 30, 2015, the Company drew down the remaining $5 million of the term loan. The term loan was repayable in installments over forty-eight months and, at drawdown date, had an interest-only period of eighteen months after closing. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the U.S. prime rate with interest only period until December 1, 2015. The average interest rate paid by the Company during the first quarter of 2016 was 10% and 9.75% during the first of quarter of 2015.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase an aggregate of 210,675 shares of the Company’s common stock at an exercise price of $2.67 per share with a term of five years. The warrant is exercisable beginning on the date of issuance and expires May 9, 2019. The fair value of the warrants of $397,649 and financing costs of $407,253 incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $66,194 and $50,518 for the three months ended March 31, 2016 and 2015, respectively. At March 31, 2016, the remaining unamortized balance of debt issuance costs was $350,518.

In addition, the Company will pay an end of term charge of $592,500 on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan becomes due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $45,923 and $44,146 of this fee during the three months ended March 31, 2016 and 2015, respectively.

On April 25, 2016, the Company entered into an amendment agreement with Hercules which provided that the scheduled principal payments due on May 1, 2016 and the first business day of each month thereafter through and including the payment due on May 1, 2017 will be deferred (“deferred payments”). Commencing on June 1, 2017, and continuing on the first business day of each month thereafter, the Company will recommence scheduled payments of principal and interest based on original amortization period of thirty-one (31) consecutive months with a balloon payment of all the deferred payments included in the last installment. The deferred payments and all other accrued but unpaid interest will be due and payable on the loan maturity date of June 1, 2018. The current portion of debt on the consolidated balance sheet and the summary of payments disclosed below were adjusted for this amendment.

Long-term debt as of March 31, 2016 and December 31, 2015, consists of the following:

	March 31, 2016			December 31, 2015

Loan payable	$	13,275,698		$	14,572,558
End of term fee		349,320			303,398
		13,625,018			14,875,956
Deferred debt issuance costs		(350,518	)		(416,712	)
		13,274,500			14,459,244
Less: Current portion		(436,690	)		(5,378,134	)
Long-term debt	$	12,837,810		$	9,081,110

The summary of payments due on the term loan as of March 31, 2016, is as follows:

2016	$	436,690
2017		2,603,824
2018		10,827,684
Total loan payments		13,868,198
Less end of term fee		(592,500	)
	$	13,275,698

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

Stockholders’ Equity

Public Offering of Common Stock

On March 29, 2016, the Company completed a public offering of 4,600,000 shares of the Company's common stock, including the exercise in full of the underwriters’ overallotment option to purchase up an additional 600,000 shares of common stock at the public offering price of $9.50 per share. The gross proceeds of this offering were $43.7 million. Net proceeds to the Company, after deducting the underwriters' discounts and commission and other offering expenses payable by the Company, were $40.6 million.

At-The-Market Equity Offering Program

On October 16, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) to sell shares of common stock with aggregate gross proceeds of up to $20.0 million, from time to time, through an “at-the-market” equity offering program under which Cantor will act as sales agent. The Sales Agreement provides that Cantor will be entitled to compensation for its services in an amount equal to 3.0% of the gross proceeds from the sales of shares sold under the Sales Agreement.

During the first quarter of 2016, the Company sold 1,353,900 shares of common stock under the Sales Agreement at $7.43 per share for gross proceeds of $10.1 million and net proceeds of $9.8 million, after deducting Cantor’s commission. As of March 31, 2016, $7.9 million of common stock remains available to be sold under this facility.

Warrants

During the first quarter of 2016, 321,384 warrants were exercised with a weighted average exercise price of $2.99 of which 85,170 shares were withheld to satisfy the exercise price. A total of 12,445 warrants with a weighted average exercise price of $11.25 expired during the quarter. The following table summarizes the warrants outstanding to purchase common stock at March 31, 2016:

Issue date	Number of warrants		Exercise price		Term	Expiry
December 2011		123,585	$	5.21	7 years	December 2018
February 2012		3,700	$	5.21	6 years	February 2018
June 2012		17,267	$	5.21	7 years	June 2019
August 2012		112,536	$	5.21	7 years	August 2019
April 2013		159,806	$	5.21	7 years	April 2020
April 2013		3,934,649	$	3.58	7 years	April 2020
October 2014		807,777	$	3.58	5 years	October 2019
		5,159,320

10.

Stock Based Compensation

2013 Equity Incentive Plan

In 2013, the Company adopted the Celator Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”). Options granted under the Plan may be incentive stock options or non-qualified stock options. Incentive stock options may only be granted to employees. The board of directors, or a committee of the board of directors appointed to administer the Plan, determines the period over which options become exercisable and the conditions under which stock awards are granted and become vested.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2016:

		Number of options			Weighted Average Exercise price		Weighted Average Remaining Contractual Life (Yrs)		Aggregate Intrinsic Value

Outstanding at	December 31, 2015		3,944,571		$	2.90
	Granted		1,599,024			1.32
	Exercised		(100,087	)		2.25
	Cancelled		(5,334	)		2.25
Outstanding at	March 31, 2016		5,438,174		$	2.45		8.1	$	46,686,011

Exercisable at	March 31, 2016		2,488,458		$	2.73		7.1	$	20,650,985

During the three months ended March 31, 2016, 12,081 shares were withheld to satisfy the exercise of certain stock options exercised during the period.

In January 2016, the Company granted 397,024 stock options, included in the options granted above, to certain employees as payment of $365,262 of bonuses earned and accrued as of December 31, 2015. In February 2015, the Company issued 60,517 shares of common stock to certain Company employees as payment of $168,843 of bonuses earned and accrued as of December 31, 2014.

The following table provides information regarding stock options activity for the three months ended March 31, 2016 and 2015:

	Three months ended
	March 31
	2016			2015
Stock compensation expense recognized	$	576,070		$	359,200
Weighted average grant-date fair value of stock options issued (per share)	$	1.03		$	2.31
Grant-date fair value of stock options issued	$	1,651,472		$	1,360,094
Volatility		98.8	%		106.9	%
Risk-free interest rate		1.7	%		1.7	%
Dividend yield		0	%		0	%
Expected life in years		5.9			6.2
Intrinsic value of stock options exercised	$	669,582		$	-

The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.

The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At March 31, 2016, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $4,850,285 and 2.5 years, respectively.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

11.

Geographic Segment Information

The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.

	Total Assets
	March 31, 2016		December 31, 2015
United States	$	68,531,389	$	24,256,629
Canada		156,905		204,283
Germany		717,258		757,560
Total Assets	$	69,405,552	$	25,218,472

	Net Loss
	Three months ended
	March 31
	2016			2015
United States	$	(5,199,096	)	$	(4,311,341	)
Canada		(334,227	)		(399,642	)
Total Net Loss	$	(5,533,323	)	$	(4,710,983	)

12.

Commitments and Contingencies

In September 2015, the Company entered into a lease agreement for office and laboratory space in Vancouver, British Columbia, which expires in August 2017. The remaining minimum lease payments as of March 31, 2016 were $159,700. The Company also vacated its previous lease for office space effective October 1, 2015. The vacated lease expires in June 2016.

In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of March 31, 2016 were $322,000. Under the Ewing, New Jersey lease agreement, the Company will be obligated to maintain a letter of credit from a bank with respect to its security deposit obligations in the amount of $200,000 during the first year of the Agreement and the deposit is reduced annually through lease expiration date. The restricted deposit balance as of March 31, 2016 was $120,000.

The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in the Company’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45% to 55% of proceeds obtained from a sub-license of the intellectual property to a third party in cases where the Company has not conducted any research or development activities and is solely licensing out the original intellectual property jointly developed by the Company and Princeton University. The Company may terminate the agreement at any time by giving 90 days written notice to Princeton University. Princeton may terminate the agreement if the Company should breach or fail to perform under the agreement, with written notice of default provided by Princeton University to the Company and only if the Company fails to cure the default within 60 days. The Company is obligated under the agreement to provide an annual progress report to Princeton University on any developments of the licensed technology as well as prosecution of the patents covering the technology and the use of commercially reasonable efforts to develop licensed products.

Celator Pharmaceuticals, Inc. and Subsidiaries

Notes to the Consolidated Financial Statements

(Unaudited)

The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 days.

In consideration of funding by LLS and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a cash multiple on the LLS funding, (LLS funding is the $5 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of the Phase 2 study). Subject to exclusions under the agreement, the Company is obligated to pay LLS an amount equal to 50% of the cash payments the Company receives from out-licenses and transfers of rights to the product or other liquidity event, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding the Company receives from LLS. The total amount payable by the Company to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties (not to exceed 5% of net sales) but will not exceed the maximum amount referred to in the preceding sentence.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties that may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning. One can also identify them by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements contained in this Form 10-Q quarterly report include, among others, statements about the sufficiency of its capital to fund its estimated working capital requirements and operations into 2018, the expected timeline for its milestones in connection with its Phase 3 clinical study, its product pipeline, statements regarding the efficacy of the Company's CombiPlex® technology, the safety, tolerability, efficacy and therapeutic potential of VYXEOS^TM, whether clinical results for VYXEOS obtained to date will be predictive of future clinical study results, the Company's expectations regarding the Company's development plans for VYXEOS and our drug candidates, and the Company's expectations about expanding the Company's product pipeline and advancing the Company's CombiPlex platform. Forward-looking statements in this Form 10-Q quarterly report involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, capital market conditions, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s drug candidates, and the Company’s ability to pay its debt obligations on a timely basis or otherwise pay its expenses and enhance its liquidity position. Forward-looking statements in this Form 10-Q quarterly report involve substantial risks and uncertainties that could cause the Company's clinical development programs, future results, performance of achievements to differ significantly from those expressed or implied in the forward-looking statements. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.

Overview

On March 14, 2016 we reported positive results from our Phase 3 study of VYXEOS in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. The median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS. The hazard ratio (HR) was 0.69 (p=0.005) which represents a 31 percent reduction in the risk of death versus 7+3. The percentage of patients alive 12 months after randomization was 41.5% on the VYXEOS arm compared to 27.6% on the 7+3 arm. The percentage of patients alive 24 months after randomization was 31.1% on the VYXEOS arm compared to 12.3% on the 7+3 arm.

VYXEOS also demonstrated a statistically significant improvement in induction response rate (CR+CRi of 47.7% versus 33.3%; p=0.016) and this significance was maintained for the analysis of CR alone (CR of 37.3% versus 25.6%, p=0.040). Sixty-day all-cause mortality was 13.7% versus 21.2%, in favor of patients treated with VYXEOS.

No substantial difference in Grade 3 or higher adverse events was observed between VYXEOS and 7+3. In the intent-to-treat population, Grade 3 or higher, hematologic adverse events were similar for overall infections, febrile neutropenia, and bleeding events. In the intent-to-treat population, Grade 3 or higher, non-hematologic adverse events were similar across all organ systems, including cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.

Our current plans for VYXEOS assume the following key dates:

	·	3Q 2016 – New Drug Application (NDA) submission.
	·	1Q 2017 – Marketing Authorization Application (MAA) submission.
	·	Mid 2017 – Prescription Drug User Fee Act (PDUFA) date (assuming FDA grants priority review).
	·	3Q 2017 – US Commercial Launch (assuming FDA approval in mid-2017)
	·	1Q 2018 – Committee for Medicinal Products for Human Use (CHMP) opinion date.

There are a number of additional VYXEOS clinical studies either ongoing or planned. These clinical development activities are designed to evaluate VYXEOS in other AML patient populations as well as other blood cancers. The studies are taking into consideration a variety of patient variables, including, but not limited to, age, suitability (or fitness) for intensive treatment, and patients’ line of therapy (first line, relapse, and refractory).

AML is a cancer of the bone marrow and blood. It affects mostly cells that are not fully developed and these cells cannot carry out their normal functions. AML has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.

AML accounts for 25 percent of all adult leukemias in the Western world, with the highest incidence rates occurring in the United States, Australia and Europe. AML is generally a disease of older adults, and the median age at the time of diagnosis is about 66 years. AML has one of the lowest survival rates of all leukemias. In 2016, the American Cancer Society’s Cancer Facts & Figures estimates 19,950 new cases in the U.S. In Europe and in Japan, the incidence is reported to be approximately 18,000 and 5,500 new cases, respectively. Untreated AML in all ages is rapidly fatal, with patients dying on average within a few months of diagnosis. Even with treatment, the median overall survival of newly diagnosed AML patients is approximately 12 months, with particular groups of AML patients, including those with high-risk (secondary) AML, having a poorer prognosis (median overall survival 6-7 months).

We own worldwide development and commercialization rights to VYXEOS. In 2008, the Food and Drug Administration (“FDA”) granted orphan drug designation to VYXEOS for the treatment of AML. In 2012, the European Commission granted orphan drug status to VYXEOS for the treatment of AML. In January 2015, the FDA granted fast track designation to VYXEOS for the treatment of elderly patients with secondary AML. We have been granted, or notified of allowance of, a number of key patents for VYXEOS.

VYXEOS is based on our proprietary technology platform, CombiPlex®, which enables the rational design and rapid evaluation of optimized drug combinations to deliver enhanced anti-cancer activity. The platform can utilize traditional chemotherapies as well as molecularly targeted agents. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor.

There is considerable time and cost associated with developing a potential drug or pharmaceutical product to the point of regulatory approval and commercialization. To date, we have funded our operations primarily through private placements of preferred stock, private and public placements of common stock, convertible debt and debt financings. In the future, we may also pursue additional funding options, including entering into agreements with collaborative partners. We believe that the cash and cash equivalents of $67.5 million at March 31, 2016 will be sufficient to meet estimated working capital requirements and fund operations into 2018. We expect to continue to incur losses as we fund research and development and commercial launch activities, and we do not expect material revenues for at least the next few years.

Results of Operations

Three months ended March 31, 2016 compared to the three months ended March 31, 2015

Expenses

Research and Development: Research and development expenses consist largely of costs directly attributable to the conduct of research and development programs, including the cost of salaries and related benefits, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses and the full cost of manufacturing drug. All costs associated with research and development are expensed as incurred.

The following table summarizes research and development spending:

	Three months ended
	March 31
	2016		2015
VYXEOS Phase 3 – Study (301)	$	2,465,000	$	2,321,000
CombiPlex Platform Technology Advancement		111,000		207,000
Intellectual Property (legal and patent costs)		81,000		82,000
General Research (professional development, recruitment, etc.)		32,000		98,000
Totals	$	2,689,000	$	2,708,000

Research and development expenses were $2,689,000 for the three months ended March 31, 2016 compared to $2,708,000 for the three months ended March 31, 2015 reflecting a decrease of $19,000. The decrease was primarily attributable to $121,000 decrease in manufacturing and drug and lipid costs, and $63,000 decrease in laboratory research costs and CombiPlex Platform technology advancement costs. These decreases were offset by increases in compensation and stock option expenses of $68,000, stability and validation studies of $70,000, and outsourced clinical trial and regulatory activities related to the Phase 3 trial and new drug application preparation of VYXEOS of $28,000.

LLS Funding: The LLS revenue recognized for the three months ended March 31, 2016 was $145,000 compared to $136,000 for 2015, reflecting an increase of $9,000. The $145,000 recognized in 2016 represents an earned milestone of $100,000 from LLS for the milestone achieved relating to the primary end-point analysis of the Phase 3 trial of VYXEOS during the quarter, and amortization of a $2,000,000 upfront payment received during 2012 of $45,000.The amount recognized during the three months ended March 31, 2015 represents the amortization the upfront payment received during 2012 of $136,000.

General and Administrative: General and administrative expenses consist largely of salaries and related benefits, external costs for professional fees relating to legal, accounting and tax services, lease expense for the facilities, public company related costs and external consulting costs associated with investor relations, commercial operations and strategic planning.

General and administrative expenses were $2,469,000 for the three months ended March 31, 2016 compared to $1,761,000 for the three months ended March 31, 2015, reflecting an increase of $708,000. The increase was primarily attributable to $282,000 increase in compensation and stock option expense, $367,000 increase in commercial operations, $34,000 increase in professional fees, $21,000 increase in public company costs and $20,000 increase in investor relations and strategic consulting.

Amortization and Depreciation: Amortization and depreciation expense was $48,000 for the three months ended March 31, 2016 and $49,000 for the three months ended March 31, 2015.

Other Income and Expenses

Interest Expense: Interest expense was $459,000 and $341,000 for the three months ended March 31, 2016 and 2015, respectively and was related to interest on a Hercules term loan entered into in May 2014. Interest expense of $459,000 for the three months ended March 31, 2016 includes $112,000 related to non-cash amortization of deferred financing costs and the accrual of the end of term charge. Interest expense of $341,000 for the three months ended March 31, 2015 included $95,000 related to non-cash amortization of deferred financing costs and the accrual of the end of term charge.

Liquidity and Capital Resources

Overview

There is considerable time and cost associated with developing a potential drug or pharmaceutical product to the point of regulatory approval and commercialization. To date, we have funded our operations primarily through private placements of preferred stock, private and public placements of common stock, convertible debt and debt financings. In the future, we may also pursue additional funding options, including entering into agreements with collaborative partners. We believe that the cash and cash equivalents of $67.5 million at March 31, 2016 will be sufficient to meet estimated working capital requirements and fund operations into 2018. We expect to continue to incur losses as we fund research and development activities and commercial launch activities, and we do not expect material revenues for at least the next few years.

Substantial additional funding will be needed by the Company to fund its operations and to commercialize its product candidates. Our future capital requirements will depend on many factors, including those factors described in Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 as well as our ability to execute on our business and strategic plans as currently conceived.

On October 16, 2015, we entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent, to sell shares of common stock with aggregate gross proceeds of up to $20.0 million, from time to time, through an “at-the-market” equity offering program. The Sales Agreement provides that the sales agent will be entitled to compensation for its services in an amount equal to 3.0% of the gross proceeds from the sales of shares sold under the Sales Agreement. During the first quarter of 2016, we sold 1,353,900 shares of common stock under the Sales Agreement at $7.43 per share for gross proceeds of $10.1 million and net proceeds of $9.8 million, after deducting the sales agent’s commission. As of March 31, 2016, $7.9 million of common stock remains available to be sold under this facility.

On April 25, 2016, the Company entered into an amendment agreement with Hercules which provided that the scheduled principal payments due on May 1, 2016 and the first business day of each month thereafter through and including the payment due on May 1, 2017 will be deferred (“deferred payments”). Commencing on June 1, 2017, and continuing on the first business day of each month thereafter, the Company will recommence scheduled payments of principal and interest based on the original amortization period of thirty-one (31) consecutive months with a balloon payment of all the deferred payments included in the last installment. The deferred payments and all other accrued but unpaid interest will be due and payable on the loan maturity date of June 1, 2018.

In June 2012, we entered into an agreement with LLS pursuant to which LLS is providing $5.0 million in funding from the LLS Therapy Acceleration Program (“TAP”) program for the Phase 3 study of VYXEOS. The agreement provided for LLS to make an upfront payment of $2.0 million, which was received in July 2012, and further payments totaling an additional $3.0 million on the achievement of clinical milestones; however, the amount may be refundable by the Company in the event of a material breach by us under the agreement. Through March 31, 2016 we have received the $5.0 million in funding from the LLS.

In consideration of LLS’s funding, and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, we must pay LLS a multiple on the LLS funding. (LLS funding is the $5.0 million in support of the Phase 3 study in addition to the approximately $4.1 million the Company received in support of a Phase 2 study during 2010 and 2011). Subject to exclusions under the agreement, we are obligated to pay LLS an amount equal to 50% of the cash payments we receive from out licenses and transfers of rights to the product or other liquidity events, as defined in the agreement, until LLS has received an amount equal to 1.5 times the amount of funding we received from LLS. There may also be royalties due to LLS, not to exceed 5% of net sales. The total amount payable by us to LLS will not exceed 3.55 times the amount of funding received from LLS, with the specific amount depending on when the payment(s) occur relative to the timing of the research program and product commercialization. The payments may take the form of cash payments or royalties but will not exceed the maximum amount referred to in the preceding sentence.

Cash Flows

Net cash used in operating activities was $5,106,000 for the three months ended March 31, 2016. The three months ended March 31, 2016 amount reflected the Company’s net loss of $5,533,000, offset by $736,000 in net non-cash charges including stock-based compensation expense of $576,000, non-cash interest expense of $112,000 related to the Hercules loan, and amortization and depreciation of $48,000. In addition, the Company used $309,000 of operating cash as a result of changes in certain of its operating assets and liabilities during the three months ended March 31, 2016. The changes in operating assets and liabilities were decreases in accounts payable of $385,000, deferred revenue of $45,000, deferred rent of $3,000 and increase in other receivables of $42,000. Offsetting these changes were decreases in prepaid expenses and deposits of $95,000, other current assets of $8,000, and other non-current assets of $1,000 and an increase in accrued expenses of $63,000,.

Net cash used in operating activities was $4,494,000 for the three months ended March 31, 2015. The three months ended March 31, 2015 amount reflected the Company’s net loss of $4,711,000, offset by $503,000 in net non-cash charges including non-cash interest expense of $95,000 related to the Hercules loan, amortization and depreciation of $49,000, and stock-based compensation expense of $359,000. In addition, the Company used $286,000 of operating cash as a result of changes in certain of its operating assets and liabilities during the three months ended March 31, 2015. The changes in operating assets and liabilities were decreases in accrued expenses of $285,000, deferred revenue of $136,000, deferred rent of $2,000 and increase in other receivables of $5,000. Offsetting these changes were decreases in prepaid expenses and deposits of $80,000, other current assets of $16,000, and increase in accounts payable of $46,000.

Cash used in investing activities was $3,000 for the three months ended March 31, 2016 for acquisition of property and equipment. Cash used in investing activities was $18,000 for the three months ended March 31, 2015 for acquisition of property and equipment.

Cash provided by financing activities for the three months ended March 31, 2016 was $49,396,000. The cash inflow was from the net proceeds from issuance of common stock and exercise of stock options and warrants of $50,692,000 offset by $1,297,000 for the repayment of the debt. Cash provided by financing activities was $5,000,000 for the three months ended March 31, 2015 for proceeds from a loan.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, other than operating leases, that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.

Critical Accounting Policies

The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2015 included in Celator Pharmaceuticals Inc.’s Form 10-K filed. There have been no significant changes in the Company’s critical accounting policies since December 31, 2015.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The Company invests excess cash in investment grade, interest-bearing securities and at March 31, 2016, had approximately $17.2 million invested in money market instruments. Such investments are subject to interest rate and credit risk and are not fully insured by the federal government. The Company believes its policy of investing in highly rated securities, whose liquidities are, at March 31, 2016, all less than 90 days minimizes such risks. In addition, while a hypothetical one percent per annum decrease in market interest rates would have decreased the Company’s interest income for the period, it would not have resulted in a loss of the principal and the decline in interest income would have been immaterial to the Company.

The Company had outstanding total debt at March 31, 2016 of $13.3 million. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the U.S. prime rate. The average interest rate paid by the Company during the first quarter of 2016 was 10%.

The majority of the Company’s business is conducted in U.S. dollars. However, the Company does conduct certain transactions in other currencies, including Canadian dollars. Historically, fluctuations in foreign currency exchange rates have not materially affected the Company’s results of operations, and during the three months ended March 31, 2016 and 2015, the Company’s results of operations were not materially affected by fluctuations in foreign currency exchange rates.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s (the “Commission”) rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

Change in Internal Control over Financial Reporting

No change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II. Other Information

Item 1.

Legal Proceedings

There are no material pending legal proceedings.

Item 1A.

Risk Factors

Except for the historical information in this report, the matters contained in this report include forward-looking statements that involve risks and uncertainties. Our operating results and financial condition have varied in the past and may in the future vary significantly depending on a number of factors. These factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this report and presented elsewhere by management from time to time. Such factors may have a material adverse effect upon our business, results of operations and financial condition.

You should consider carefully the risk factors, together with all of the other information included in our Annual Report on Form 10-K for the year ended December 31, 2015. Each of these risk factors could adversely affect our business, results of operations and financial condition, as well as adversely affect the value of an investment in our common stock. There have been no material changes to our risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

There were no sales of unregistered equity securities during the three months ended March 31, 2016. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

Item 6.

Exhibits

Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index hereto and include the following:

Exhibit No.		Description
3.1		Third Amended and Restated Certificate of Incorporation of the Company, as amended. (Incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q quarterly report filed on August 7, 2014.)

3.2		Amended and Restated By-laws of the Company. (Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K current report filed on April 18, 2013.)

10.1		Amendment to Employment Agreement dated as of April 1, 2016 between Celator Pharmaceuticals, Inc. and Scott T. Jackson (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K current report filed on April 5, 2016).

10.2		Amendment to Employment Agreement dated as of April 1, 2016 between Celator Pharmaceuticals, Inc. and Dr. Lawrence Mayer (Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K current report filed on April 5, 2016).

10.3		Amendment to Employment Agreement dated as of April 1, 2016 between Celator Pharmaceuticals, Inc. and Fred M. Powell (Incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K current report filed on April 5, 2016).

10.4		Amendment No. 1 to Loan and Security Agreement dated April 25, 2016 among Celator Pharmaceuticals, Inc., Celator Pharmaceuticals Corp. and Hercules Capital, Inc. (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K current report filed on April 27, 2016)

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

32.1		Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.

101.1		The following financial statements from Celator Pharmaceuticals Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets at March 31 2016 and December 31, 2015, (ii) the Statements of Loss for the three months ended March 31, 2016 and 2015, (iii) Statement of Shareholders’ Equity for the three months ended March 31, 2016, (iv) the Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015, and (v) Notes to Consolidated Financial Statements.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELATOR PHARMACEUTICALS, INC.


Signature	Title	Date

/s/ Scott T. Jackson Scott T. Jackson	Chief Executive Officer and a Director (principal executive officer)	May 10, 2016

/s/ Fred M. Powell Fred M. Powell	Vice President and Chief Financial Officer (principal financial and accounting officer)	May 10, 2016

EXHIBIT INDEX

Exhibit No.		Description

3.1		Third Amended and Restated Certificate of Incorporation of the Company, as amended. (Incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q quarterly report filed on August 7, 2014.)

3.2		Amended and Restated By-laws of the Company. (Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K current report filed on April 18, 2013.)

10.1		Amendment to Employment Agreement dated as of April 1, 2016 between Celator Pharmaceuticals, Inc. and Scott T. Jackson (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K current report filed on April 5, 2016).

10.2		Amendment to Employment Agreement dated as of April 1, 2016 between Celator Pharmaceuticals, Inc. and Dr. Lawrence Mayer (Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K current report filed on April 5, 2016).

10.3		Amendment to Employment Agreement dated as of April 1, 2016 between Celator Pharmaceuticals, Inc. and Fred M. Powell (Incorporated by reference to Exhibit 10.3 to the Company’s Form 8-K current report filed on April 5, 2016).

10.4		Amendment No. 1 to Loan and Security Agreement dated April 25, 2016 among Celator Pharmaceuticals, Inc., Celator Pharmaceuticals Corp. and Hercules Capital, Inc. (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K current report filed on April 27, 2016)

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.

32.1		Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer.

101.1		The following financial statements from Celator Pharmaceuticals Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets at March 31 2016 and December 31, 2015, (ii) the Statements of Loss for the three months ended March 31, 2016 and 2015, (iii) Statement of Shareholders’ Equity for the three months ended March 31, 2016, (iv) the Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015, and (v) Notes to Consolidated Financial Statements.

EX-31.1 2 v437910_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Chief Executive Officer Pursuant to

Exchange Act Rules 13a-14(a) or 15d-14(a)

I, Scott T. Jackson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Celator Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 10, 2016			/s/ Scott T. Jackson
			Scott T. Jackson,
			Chief Executive Officer

EX-31.2 3 v437910_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Chief Financial Officer Pursuant to

Exchange Act Rules 13a-14(a) or 15d-14(a)

I, Fred M. Powell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Celator Pharmaceuticals, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2016				/s/ Fred M. Powell
				Fred M. Powell, Vice President and
				Chief Financial Officer

EX-32.1 4 v437910_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350,

In connection with the quarterly report of Celator Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2016				/s/ Scott T. Jackson
				Scott T. Jackson,
				Chief Executive Officer
				(Principal executive officer)

Date: May 10, 2016				/s/ Fred M. Powell
				Fred M. Powell, Vice President and
				Chief Financial Officer
				(Principal financial and accounting officer)

EX-101.INS 5 cpxx-20160331.xml XBRL INSTANCE DOCUMENT 0001327467 2014-01-01 2014-12-31 0001327467 2015-01-01 2015-03-31 0001327467 2015-01-01 2015-12-31 0001327467 2016-01-01 2016-03-31 0001327467 2016-03-31 0001327467 2016-05-06 0001327467 2015-12-31 0001327467 2014-12-31 0001327467 2015-03-31 0001327467 us-gaap:CommonStockMember 2016-03-31 0001327467 us-gaap:WarrantMember 2016-03-31 0001327467 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001327467 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-03-31 0001327467 us-gaap:RetainedEarningsMember 2016-03-31 0001327467 us-gaap:WarrantMember 2015-12-31 0001327467 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001327467 us-gaap:RetainedEarningsMember 2015-12-31 0001327467 us-gaap:CommonStockMember 2015-12-31 0001327467 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001327467 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001327467 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001327467 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001327467 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-03-31 0001327467 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001327467 us-gaap:FairValueInputsLevel1Member 2016-03-31 0001327467 us-gaap:FairValueInputsLevel2Member 2016-03-31 0001327467 us-gaap:FairValueInputsLevel3Member 2016-03-31 0001327467 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001327467 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001327467 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001327467 us-gaap:ComputerEquipmentMember 2015-12-31 0001327467 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001327467 us-gaap:EquipmentMember 2015-12-31 0001327467 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2015-12-31 0001327467 us-gaap:ComputerEquipmentMember 2016-03-31 0001327467 us-gaap:FurnitureAndFixturesMember 2016-03-31 0001327467 us-gaap:EquipmentMember 2016-03-31 0001327467 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2016-03-31 0001327467 us-gaap:AssetsHeldUnderCapitalLeasesMember 2015-12-31 0001327467 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2014-05-09 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember us-gaap:WarrantMember 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember cpxx:TermLoansMember 2016-01-01 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember cpxx:TermLoanMember 2016-01-01 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember cpxx:TermLoanMember 2015-01-01 2015-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember cpxx:TermLoanMember 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember cpxx:EndOfTermFeesMember 2016-01-01 2016-03-31 0001327467 cpxx:EndOfTermFeesMember cpxx:HerculesTechnologyGrowthCapitalMember 2015-01-01 2015-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2015-03-01 2015-03-30 0001327467 cpxx:ControlledEquityOfferingSalesAgreementMember 2015-10-16 0001327467 cpxx:ControlledEquityOfferingSalesAgreementMember 2015-10-01 2015-10-16 0001327467 cpxx:DecemberTwoThousandElevenMember 2016-03-31 0001327467 cpxx:FebruaryTwoThousandTwelveMember 2016-03-31 0001327467 cpxx:AugustTwoThousandTwelveMember 2016-03-31 0001327467 cpxx:AprilTwoThousandThirteenMember 2016-03-31 0001327467 cpxx:AprilTwoThousandThirteenOneMember 2016-03-31 0001327467 cpxx:OctoberTwoThousandFourteenMember 2016-03-31 0001327467 country:US 2015-12-31 0001327467 country:CA 2015-12-31 0001327467 country:DE 2015-12-31 0001327467 country:US 2016-03-31 0001327467 country:CA 2016-03-31 0001327467 country:DE 2016-03-31 0001327467 country:US 2016-01-01 2016-03-31 0001327467 country:CA 2016-01-01 2016-03-31 0001327467 country:US 2015-01-01 2015-03-31 0001327467 country:CA 2015-01-01 2015-03-31 0001327467 cpxx:EwingNewJerseyMember 2016-03-31 0001327467 cpxx:EwingNewJerseyMember 2013-06-30 0001327467 cpxx:ColumbiaMember 2016-03-31 0001327467 cpxx:LeukemiaAndLymphomaSocietyAgreementMember 2016-01-01 2016-03-31 0001327467 cpxx:PhaseThreeStudyMember cpxx:LeukemiaAndLymphomaSocietyAgreementMember 2016-01-01 2016-03-31 0001327467 cpxx:PhaseTwoStudyMember cpxx:LeukemiaAndLymphomaSocietyAgreementMember 2016-01-01 2016-03-31 0001327467 cpxx:LeukemiaAndLymphomaSocietyAgreementMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001327467 cpxx:LeukemiaAndLymphomaSocietyAgreementMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001327467 cpxx:PrincetonUniversityAgreementMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001327467 cpxx:PrincetonUniversityAgreementMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001327467 cpxx:PrincetonUniversityAgreementMember 2016-01-01 2016-03-31 0001327467 cpxx:BritishColumbiaCancerAgencyMember 2016-01-01 2016-03-31 0001327467 us-gaap:StockOptionMember 2015-12-31 0001327467 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0001327467 us-gaap:StockOptionMember 2016-03-31 0001327467 cpxx:PublicOfferingMember 2016-03-01 2016-03-29 0001327467 us-gaap:CommonStockMember cpxx:PublicOfferingMember 2016-03-01 2016-03-29 0001327467 cpxx:PublicOfferingMember us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2016-03-01 2016-03-29 0001327467 us-gaap:CommonStockMember cpxx:PublicOfferingMember 2016-03-29 0001327467 cpxx:ControlledEquityOfferingSalesAgreementMember 2016-01-01 2016-03-31 0001327467 cpxx:ControlledEquityOfferingSalesAgreementMember 2016-03-31 0001327467 cpxx:NonVestedAwardsMember 2016-01-01 2016-03-31 0001327467 cpxx:NonVestedAwardsMember 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2016-01-01 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2015-01-01 2015-03-31 0001327467 us-gaap:ScenarioPreviouslyReportedMember 2015-12-31 0001327467 us-gaap:RestatementAdjustmentMember 2015-12-31 0001327467 cpxx:DecemberTwoThousandElevenMember 2016-01-01 2016-03-31 0001327467 cpxx:FebruaryTwoThousandTwelveMember 2016-01-01 2016-03-31 0001327467 cpxx:AugustTwoThousandTwelveMember 2016-01-01 2016-03-31 0001327467 cpxx:AprilTwoThousandThirteenMember 2016-01-01 2016-03-31 0001327467 cpxx:AprilTwoThousandThirteenOneMember 2016-01-01 2016-03-31 0001327467 cpxx:OctoberTwoThousandFourteenMember 2016-01-01 2016-03-31 0001327467 cpxx:HerculesTechnologyGrowthCapitalMember 2014-05-01 2014-05-09 0001327467 cpxx:JuneTwoThousandTwelveMember 2016-03-31 0001327467 cpxx:JuneTwoThousandTwelveMember 2016-01-01 2016-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2016-03-31 2016 Q1 Celator Pharmaceuticals Inc 0001327467 --12-31 Smaller Reporting Company CPXX 42470256

23253328

67541467

149017

150921

74244

116859

421491

329800

414904

407043

24312984

68546090

861490

816438

43998

43024

25218472

69405552

778360

394369

2377713

2081544

45249

8579456

2912603

18687559

16774590

34944

41222

1083193

175229643

226856737

-1133266

-168683601

-174216924

6530913

52630962

25218472

69405552

5378134

436690

9081110

12837810

1026993

1024177

2689189

2708011

145249 135747

2468648

1761449

48347

48928

-5060935

-4382641

-15984

9639

2329

3141

458733

341122

-5533323

-4710983

-0.16

-0.14

35400496

33704889

52630962

41222

1083193

226856737

-1133266

-174216924

41222270

1083193

-1133266

-168683601

34944

175229643

6530913

34944150

-5533323

359200

576070

94664

112117

4864

42362

-79617

-94826

-16266

-7861

46113

-385118

-285171

62979

-135746

-45249

-4494202

-5105662

17938

3295

-17938

-3295

51105723

5000000

49395505

-3825

1591

484035

44288139

32413777

32897812

243750

356166

1296861

-1012

413357

17194140

22162678

17194140

22162678

117135

73863

1754608

54732

118935

73863

1754608

56227

1294372

1342719

155524

723039

254425

1029488 1042050 174376 267802

202059

194438

123867

114319

124884

208510

15000000

10000000

2.67

407253

66194

50518

350518

210675

592500

397649

45923

44146

5000000

14572558

13275698

303398 349320

2603824

10827684

13868198

13275698

592500 0.030 20000000

123585

3700

112536

159806

3934649

807777

5.21

3.58

24256629

204283

757560

68531389

156905

717258

-5199096

-334227

-4311341

-399642

322000

200000

159700

120000

0.5 5000000 4100000 1.5 3.55 0.45 0.55 P90D P60D P45D

20000000

0.001

200000000

0.001

41222270

34944150

-2816

-2218

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div style="CLEAR:both;CLEAR: both"><b>1.</b></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><b>Nature of Business and Liquidity</b></div> </td> </tr> </table> <b><font style="FONT-SIZE: 10pt"> </font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Our proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor. Our lead product is VYXEOS<sup style="font-style:normal">TM</sup>, a nano-scale liposomal formulation of cytarabine:daunorubicin, completed a Phase 3 clinical trial for the treatment of acute myeloid leukemia (AML). On March 14, 2016 we reported positive results from our Phase 3 study of VYXEOS in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, we have advanced the CombiPlex platform and broadened its application to include molecularly targeted therapies.</div> <font style="FONT-SIZE: 10pt"> </font> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company has incurred recurring losses and negative cash flows from operations since inception. As of March 31, 2016, the Company had an accumulated deficit <font style="BACKGROUND-COLOR: transparent">of <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">174.2</font> million</font>. The Company</font> expects operating losses and negative cash flows to continue for the foreseeable future until such time, if ever, that it can generate significant revenues from its product candidates currently in development. Management believes that the cash and cash equivalents of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">67.5</font> million at March 31, 2016 will be sufficient to meet estimated working capital requirements and fund operations into 2018.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</font></div> <font style="FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23.05pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Use of estimates:</font></i> <font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes the cumulative effect of the change on total assets, total liabilities and stockholders’ equity in the statement of financial position as of the beginning of the period presented. The adoption of the guidance did not have any effect on loss from operations, and loss per share amounts for the current period and any prior periods.</font></div> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Deferred</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As Reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Financing Costs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Reclassification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both">Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">460,710</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">43,998</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,635,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both">Loans payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">9,497,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">9,081,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">19,104,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">18,687,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total liabilities and stockholders' equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,635,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>Total Assets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>United States</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>68,531,389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>24,256,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Canada</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>156,905</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>204,283</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Germany</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>717,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>757,560</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Total Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>69,405,552</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>Net Loss</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>March 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>United States</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(5,199,096)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(4,311,341)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Canada</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(334,227)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(399,642)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Total Net Loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(5,533,323)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(4,710,983)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div><strong>10.</strong></div> </td> <td> <div><strong>Stock Based Compensation</strong></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">2013 Equity Incentive Plan</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in; CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In 2013, the Company adopted the Celator Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”). Options granted under the Plan may be incentive stock options or non-qualified stock options. Incentive stock options may only be granted to employees. The board of directors, or a committee of the board of directors appointed to administer the Plan, determines the period over which options become exercisable and the conditions under which stock awards are granted and become vested.</font></div> </div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>Weighted Average<br/> Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average<br/> Exercise price</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>Contractual Life<br/> (Yrs)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>Aggregate<br/> Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>Outstanding at</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,944,571</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,599,024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(100,087)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,334)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>Outstanding at</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,438,174</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>8.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>46,686,011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>Exercisable at</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,488,458</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>7.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>20,650,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 23pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the three months ended March 31, 2016, 12,081 shares were withheld to satisfy the exercise of certain stock options exercised during the period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In January 2016, the Company granted 397,024 stock options, included in the options granted above, to certain employees as payment of $365,262 of bonuses earned and accrued as of December 31, 2015. In February 2015, the Company issued 60,517 shares of common stock to certain Company employees as payment of $168,843 of bonuses earned and accrued as of December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 23pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table provides information regarding stock options activity for the three months ended March 31, 2016 and 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="6"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="6"> <div>March 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Stock compensation expense recognized</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>576,070</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>359,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Weighted average grant-date fair value of stock options issued (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>2.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Grant-date fair value of stock options issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,651,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,360,094</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>98.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>106.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Expected life in years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Intrinsic value of stock options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>669,582</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At March 31, 2016, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,850,285</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.5</font> years, respectively.</font></div> <font style="FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>Weighted Average<br/> Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average<br/> Exercise price</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>Contractual Life<br/> (Yrs)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%" colspan="2"> <div>Aggregate<br/> Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>Outstanding at</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,944,571</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,599,024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(100,087)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(5,334)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>Outstanding at</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,438,174</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>8.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>46,686,011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>Exercisable at</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,488,458</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>7.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>20,650,985</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 23pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table provides information regarding stock options activity for the three months ended March 31, 2016 and 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="6"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="6"> <div>March 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Stock compensation expense recognized</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>576,070</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>359,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Weighted average grant-date fair value of stock options issued (per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>2.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Grant-date fair value of stock options issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,651,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,360,094</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>98.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>106.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Expected life in years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Intrinsic value of stock options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>669,582</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

5159320

3944571

1599024

100087

5334

5438174

2488458

2.90

1.32

2.25

2.45

2.73

46686011

20650985

P8Y1M6D

P7Y1M6D

1.03

2.31

1651472 1360094

0.988

1.069

0.017

P5Y10M24D

P6Y2M12D

669582

40600000

4600000

600000

9.50

43700000

1353900

7.43

10100000

9800000

7900000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes the warrants outstanding to purchase common stock at March 31, 2016:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 26.9pt"> <font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Issue date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Number of<br/> warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>Expiry</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="21%"> <div>December 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>123,585</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>December 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>February 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>6 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>February 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="21%"> <div>June 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>17,267</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="14%"> <div>June 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>August 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>112,536</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>August 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>April 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>159,806</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>April 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>April 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,934,649</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>April 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>October 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>807,777</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>October 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5,159,320</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div><strong>9.</strong></div> </td> <td> <div><strong>Stockholders’ Equity</strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> </font></i></strong> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Public Offering of Common Stock</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt 26.9pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On March 29, 2016, the Company completed a public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,600,000</font> shares of the Company's common stock, including the exercise in full of the underwriters’ overallotment option to purchase up an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 600,000</font> shares of common stock at the public offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.50</font> per share. The gross proceeds of this offering were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">43.7</font> million. Net proceeds to the Company, after deducting the underwriters' discounts and commission and other offering expenses payable by the Company, were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40.6</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">  </font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">At-The-Market Equity Offering Program</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt 26.9pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On October 16, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) to sell shares of common stock with aggregate gross proceeds of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20.0</font> million, from time to time, through an “at-the-market” equity offering program under which Cantor will act as sales agent. The Sales Agreement provides that Cantor will be entitled to compensation for its services in an amount equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.0</font>% of the gross proceeds from the sales of shares sold under the Sales Agreement.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the first quarter of 2016, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,353,900</font> shares of common stock under the Sales Agreement at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.43</font> per share for gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.1</font> million and net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.8</font> million, after deducting Cantor’s commission. As of March 31, 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.9</font> million of common stock remains available to be sold under this facility.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> Warrants</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="BACKGROUND-COLOR: transparent"><font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%; FONT-SIZE: 10pt"> During the first quarter of 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 321,384</font> warrants were exercised with a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.99</font> of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 85,170</font> shares were withheld to satisfy the exercise price. A total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,445</font> warrants with a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.25</font> expired during the quarter</font><font style="FONT-SIZE: 10pt">. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the warrants outstanding to purchase common stock at March 31, 2016:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 26.9pt"> <font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>Issue date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Number of<br/> warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>Expiry</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="21%"> <div>December 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>123,585</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>December 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>February 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,700</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>6 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>February 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="21%"> <div>June 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>17,267</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="14%"> <div>June 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>August 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>112,536</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>August 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>April 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>159,806</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>5.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>April 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>April 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3,934,649</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>April 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div>October 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>807,777</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>3.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>October 2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="21%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5,159,320</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P2Y6M

4850285

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">Other current assets as of March 31, 2016 and December 31, 2015, consist of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div style="CLEAR:both;CLEAR: both">Clinical trial materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">407,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">414,904</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2159157

2155862

991654

32523

35339

1024177

1026993

350518

416712

13274500

14459244

12837810

9081110

13625018

14875956

436690

0.1

0.0975

460710

-416712

25635184

-416712

9497822

-416712

19104271

-416712

25635184

-416712

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div><strong>3.</strong></div> </td> <td> <div><strong>Fair Value Measurements</strong></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. The Company believes that the current carrying amount of its long-term debt approximates fair value because interest rate on this instrument is similar to rates that the Company would be able to receive for similar instruments of comparable maturity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">FASB Accounting Standards Codification (“ASC”) Topic 820, <i>Fair Value Measurements</i> establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820-10 establishes three levels of inputs that may be used to measure fair value:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PAGE-BREAK-BEFORE: always; TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company recognizes transfers between input levels as of the actual date of event. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>There were no transfers between levels and the following table provides the assets carried at fair value:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="32%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Money Market Fund</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>17,194,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>17,194,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="32%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Money Market Fund</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>22,162,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>22,162,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P7Y P6Y P7Y P7Y P7Y P5Y December-2018 February-2018 August-2019 April-2020 April-2020 October-2019 0.05

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company recognizes transfers between input levels as of the actual date of event. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>There were no transfers between levels and the following table provides the assets carried at fair value:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>(Level 1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>(Level 2)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>(Level 3)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="32%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Money Market Fund</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>17,194,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>17,194,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="32%"> <div>Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%"> <div>Money Market Fund</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>22,162,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>22,162,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P5Y

repayable in installments over forty-eight months and, at drawdown date, had an interest-only period of eighteen months after closing

Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the U.S. prime rate with interest only period until December 1, 2015.

295640

324

295316

324220

50396400

5954

50390446

5953900

576070

365262

365262 0

168843

76897

17267

5.21

June 2019 P7Y 321384 12445 11.25

397024

365262

60517

168843

12081

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div><strong>11.</strong></div> </td> <td> <div><strong>Geographic Segment Information</strong></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>Total Assets</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>United States</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>68,531,389</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>24,256,629</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Canada</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>156,905</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>204,283</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Germany</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>717,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>757,560</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Total Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>69,405,552</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>Net Loss</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="29%" colspan="5"> <div>March 31</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>United States</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(5,199,096)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(4,311,341)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Canada</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(334,227)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(399,642)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div>Total Net Loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(5,533,323)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>(4,710,983)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div><strong>2.</strong></div> </td> <td> <div><strong>Summary of Significant Accounting Policies</strong></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of consolidation</font></i><font style="FONT-SIZE: 10pt">: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of estimates:</font></i> <font style="FONT-SIZE: 10pt"> The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><i> New Accounting Pronouncements Adopted:</i> During the period, the Company adopted Financial Accounting Standards Board (“FASB”) guidance originally issued in April 2015 which requires that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related liability, rather than as a deferred charge. The guidance was effective retroactively for financial statements covering fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the cumulative effect of the change on total assets, total liabilities and stockholders’ equity in the statement of financial position as of the beginning of the period presented. The adoption of the guidance did not have any effect on loss from operations, and loss per share amounts for the current period and any prior periods.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Deferred</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As Reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Financing Costs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Reclassification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both">Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">460,710</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">43,998</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,635,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both">Loans payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">9,497,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">9,081,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">19,104,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">18,687,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total liabilities and stockholders' equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,635,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>New Accounting Pronouncements Not Yet Effective:</font></i> <font style="FONT-SIZE: 10pt">In February 2016, the FASB issued comprehensive new guidance about leases. Under the new guidance, most leases will be recognized on an entity’s balance sheet as liabilities with corresponding right-of-use assets. The new guidance is effective for interim and annual period in fiscal years beginning after December 15, 2018, with early adoption permitted. The standard must be adopted using a modified retrospective approach. We have not yet evaluated the impact of this new pronouncement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In November 2015, the FASB issued guidance which requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The guidance is effective for public business entities for interim and annual periods in fiscal years beginning after December 15, 2016. This guidance is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.</font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August 2014, the FASB issued guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><i> New Accounting Pronouncements Adopted:</i> During the period, the Company adopted Financial Accounting Standards Board (“FASB”) guidance originally issued in April 2015 which requires that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the related liability, rather than as a deferred charge. The guidance was effective retroactively for financial statements covering fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the cumulative effect of the change on total assets, total liabilities and stockholders’ equity in the statement of financial position as of the beginning of the period presented. The adoption of the guidance did not have any effect on loss from operations, and loss per share amounts for the current period and any prior periods.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Deferred</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">As Reported</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Financing Costs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Reclassification</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both">Other assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">460,710</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">43,998</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,635,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both">Loans payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">9,497,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">9,081,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">19,104,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">18,687,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="44%"> <div style="CLEAR:both;CLEAR: both">Total liabilities and stockholders' equity</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,635,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%"> <div style="CLEAR:both;CLEAR: both">25,218,472</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>New Accounting Pronouncements Not Yet Effective:</font></i> <font style="FONT-SIZE: 10pt">In February 2016, the FASB issued comprehensive new guidance about leases. Under the new guidance, most leases will be recognized on an entity’s balance sheet as liabilities with corresponding right-of-use assets. The new guidance is effective for interim and annual period in fiscal years beginning after December 15, 2018, with early adoption permitted. The standard must be adopted using a modified retrospective approach. We have not yet evaluated the impact of this new pronouncement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In November 2015, the FASB issued guidance which requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The guidance is effective for public business entities for interim and annual periods in fiscal years beginning after December 15, 2016. This guidance is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.</font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August 2014, the FASB issued guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 22.5pt"> <div><strong>8.</strong></div> </td> <td> <div><strong>Loans Payable</strong></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On May 9, 2014, the Company entered into a term loan agreement for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million with Hercules Technology Capital Growth (“Hercules”). The first $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million of the term loan was funded at closing. On March 30, 2015, the Company drew down the remaining $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> million of the term loan. The term loan was repayable in installments over forty-eight months and, at drawdown date, had an interest-only period of eighteen months after closing. Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the U.S. prime rate with interest only period until December 1, 2015. The average interest rate paid by the Company during the first quarter of 2016 was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9.75</font>% during the first of quarter of 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 210,675</font> shares of the Company’s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.67</font> per share with a term of five years. The warrant is exercisable beginning on the date of issuance and expires May 9, 2019. The fair value of the warrants of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">397,649</font> and financing costs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">407,253</font> incurred in connection with the term loan were recorded as debt issuance costs and will be amortized as interest expense using the effective interest method over the term of the loan. Amortization of debt issuance costs was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">66,194</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,518</font> for the three months ended March 31, 2016 and 2015, respectively. At March 31, 2016, the remaining unamortized balance of debt issuance costs was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,518</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In addition, the Company will pay an end of term charge of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">592,500</font> on the earliest to occur of (i) the term loan maturity date, (ii) the date that the Company prepays the outstanding loan, or (iii) the date that the loan becomes due and payable. The end of term charge will be accrued as additional interest expense using the effective interest rate method over the term of the loan. The Company accrued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,923</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">44,146</font> of this fee during the three months ended March 31, 2016 and 2015, respectively.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On April 25, 2016, the Company entered into an amendment agreement with Hercules which provided that the scheduled principal payments due on May 1, 2016 and the first business day of each month thereafter through and including the payment due on May 1, 2017 will be deferred (“deferred payments”). Commencing on June 1, 2017, and continuing on the first business day of each month thereafter, the Company will recommence scheduled payments of principal and interest based on original amortization period of thirty-one (31) consecutive months with a balloon payment of all the deferred payments included in the last installment. The deferred payments and all other accrued but unpaid interest will be due and payable on the loan maturity date of June 1, 2018. The current portion of debt on the consolidated balance sheet and the summary of payments disclosed below were adjusted for this amendment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Long-term debt as of March 31, 2016 and December 31, 2015, consists of the following:</font></div> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Loan payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>13,275,698</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>14,572,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>End of term fee</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>349,320</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>303,398</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>13,625,018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,875,956</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Deferred debt issuance costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(350,518)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(416,712)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>13,274,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14,459,244</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Less: Current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(436,690)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(5,378,134)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Long-term debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>12,837,810</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>9,081,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.32in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The summary of payments due on the term loan as of March 31, 2016, is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.32in; WIDTH: 55%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>436,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>2,603,824</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>10,827,684</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Total loan  payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>13,868,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Less end of term fee</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>(592,500)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>13,275,698</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

85170 2.99 EX-101.SCH 6 cpxx-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Loss link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Nature of Business and Liquidity link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Other Current Assets link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Other Liabilities link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Loans Payable link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stock Based Compensation link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Geographic Segment Information link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Other Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Loans Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Geographic Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Nature of Business and Liquidity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Other Current Assets (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Other Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Loans Payable (Details) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Loans Payable (Details 1) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Loans Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Stock Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - Stock Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - Geographic Segment Information (Details) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 cpxx-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cpxx-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cpxx-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other Current Assets [Text Block] Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Accounting Policies [Abstract] Consolidation, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Domain] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Restricted Cash And Cash Equivalents At Carrying Value Restricted cash Accounts And Other Receivables Net Current Other receivables Other receivables, net Prepaid Expense Current And Noncurrent Prepaid expenses and deposits Materials, Supplies, and Other Other current assets Clinical trial materials Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property and equipment, net Property and equipment, net Other Assets Noncurrent Other assets Assets, Noncurrent Other assets Assets, Total Total assets Total Assets Total assets Liabilities [Abstract] Liabilities Liabilities Current [Abstract] Current liabilities: Long-term Debt, Current Maturities, Total Current portion of debt Less: Current portion Accounts Payable Current Accounts payable Accrued Liabilities Current Accrued liabilities Accrued liabilities Deferred Revenue Current Current portion of deferred revenue Liabilities, Current, Total Total current liabilities Other Liabilities, Noncurrent Other liabilities Preferred Stock, Value, Issued Preferred stock Authorized 20,000,000 shares, par value $0.001 Common Stock Value Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 41,222,270 and 34,944,150 shares as of March 31, 2016 and December 31, 2015, respectively Warrants And Rights Outstanding Warrants Additional Paid In Capital Additional paid-in capital Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total stockholders' equity Stockholders Equity [Abstract] Stockholders' equity Fair Value Disclosures [Abstract] Schedule of Other Current Assets [Table Text Block] Schedule of Other Current Assets [Table Text Block] Property, Plant and Equipment [Table Text Block] Schedule Of Accrued Liabilities Table [Text Block] Schedule of Accrued Liabilities [Table Text Block] Schedule of Debt [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Segment Reporting Information By Segment [Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Nature Of Business And Liquidity [Table] Legal Entity [Axis] Entity [Domain] Fair Value, by Balance Sheet Grouping [Table] Eligible Item or Group for Fair Value Option [Axis] Fair Value, Option, Eligible Item or Group [Domain] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Assets: Money Market Funds, at Carrying Value Money Market Fund Preferred Stock, Shares Authorized Preferred Stock, Par or Stated Value Per Share peferred stock, par valur (in dollars per share) Common Stock Shares Authorized Common stock, authorized shares Common Stock Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock Shares Issued Common stock, issued shares Common Stock Shares Outstanding Common stock, outstanding shares Schedule of Other Current Asset [Table] Other Current Assets [Line Items] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Computer Equipment [Member] Computer and equipment [Member] Furniture And Fixtures [Member] Furniture and office equipment [Member] Equipment [Member] Laboratory equipment [Member] Assets Held Under Capital Leases [Member] Capital lease equipment [Member] Leaseholds And Leasehold Improvements [Member] Leaseholds [Member] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Property Plant And Equipment Gross Property and equipment, gross Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Less: Accumulated depreciation Schedule Of Accrued Liabilities [Table] Accrued Liabilities [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accrued Clinical Trial Expenses Accrued clinical trial expenses Accrued Clinical Trial Expenses Accrued Bonuses Current Accrued bonuses Accrued Salaries Current Accrued salaries and vacation Accrued Drug Development Costs Accrued drug manufacturing expenses Accrued Drug Development Costs Interest Payable, Current Interest payable Other Accounts Payable And Accrued Liabilities Accrued other Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Debt Instrument [Line Items] Loans Payable Loan payable Accrued End Of Loan Term Fee End of term fee Amount of fees associated with end of loan term. Long-term Debt, Gross Long-term Debt, Gross Unamortized Debt Issuance Expense Deferred debt issuance costs Long-term Debt Total loan payments Hercules Technology Growth Capital [Member] Statement Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Warrant [Member] Warrants [Member] Term Loans [Member] End of Term Fees [Member] Stock Issued During Period, Shares, New Issues Issued for cash, net of stock issuance costs (in share) Amortization Of Financing Costs And Discounts Non-cash financing costs Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Maximum Borrowing Capacity Class of Warrant or Right, Exercise Price of Warrants or Rights Debt Issuance Cost Debt Issuance Cost Deferred Finance Costs, Noncurrent, Net Deferred financing costs (see Note 8) Long-term Debt, Maturities, Repayment Terms Line of Credit Facility, Interest Rate Description Warrants Maturity Term The number of years at exercise price of warrants to purchase in period. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Derivative Instrument [Axis] Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of options, Beginning balance Number of options, Ending balance Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of options, Granted Number of options, Granted Stock Issued During Period Shares Stock Options Exercised Number of options, Exercised Issuance of shares from exercise of stock options and warrants (in share) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Number of options, Cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Number of options, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted Average Exercise price, Beginning balance (in dollars per share) Weighted Average Exercise price, Ending balance (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Exercise price, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise price, Exercised (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Weighted Average Exercise price, Cancelled (in dollars per share) Income Statement [Abstract] Operating Expenses [Abstract] Expenses Research And Development Expense Research and development Research And Development Arrangement With Other Funding To Offset Costs Incurred Leukemia & Lymphoma Society funding The amount of funding recorded as an offset to costs incurred from arrangement with other organizations. General And Administrative Expense General and administrative Depreciation And Amortization Amortization and depreciation Operating Income Loss Operating loss Nonoperating Income Expense [Abstract] Other income (expenses) Foreign Currency Transaction Gain Loss Before Tax Foreign exchange gain (loss) Interest And Other Income Interest and miscellaneous income Interest Expense Interest expense Net Income Loss Net loss Total Net Loss Net loss Net loss for the period Earnings Per Share Basic And Diluted Basic and diluted (in dollars per share) Net loss per share Weighted Average Number Of Share Outstanding Basic And Diluted Basic and diluted (in shares) Weighted average shares outstanding Equity [Abstract] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Allocated Share-based Compensation Expense Stock compensation expense recognized Non-cash stock-based compensation expense Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value of stock options issued (per share) Share based Compensation Arrangement by Share based Payment Award Options Grants in Period Grant Date Fair Value Grant-date fair value of stock options issued Grant date fair value, Granted Grant-date fair value of options granted. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of stock options exercised Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Non vested Awards [Member] Plan Name [Axis] Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Schedule Of Revenues From External Customers And Long Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Statement Geographical [Axis] Geographical [Axis] Segment Geographical [Domain] Geographical [Domain] UNITED STATES United States CANADA Canada GERMANY Germany Revenues From External Customers And Long Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Loss Contingencies [Table] Loss Contingencies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Related Party Transactions By Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] British Columbia Cancer Agency [Member] British Columbia Cancer Agency [Member] British Columbia Cancer Agency [Member] EX-101.PRE 10 cpxx-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	May. 06, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Entity Registrant Name	Celator Pharmaceuticals Inc
Entity Central Index Key	0001327467
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CPXX
Entity Common Stock, Shares Outstanding		42,470,256

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 67,541,467	$ 23,253,328
Restricted cash	150,921	149,017
Other receivables	116,859	74,244
Prepaid expenses and deposits	329,800	421,491
Other current assets	407,043	414,904
Total current assets	68,546,090	24,312,984
Property and equipment, net	816,438	861,490
Other assets	43,024	43,998
Total assets	69,405,552	25,218,472
Current liabilities:
Current portion of debt	436,690	5,378,134
Accounts payable	394,369	778,360
Accrued liabilities	2,081,544	2,377,713
Current portion of deferred revenue	0	45,249
Total current liabilities	2,912,603	8,579,456
Other liabilities	1,024,177	1,026,993
Loans payable	12,837,810	9,081,110
Total liabilities	16,774,590	18,687,559
Stockholders' equity
Preferred stock Authorized 20,000,000 shares, par value $0.001	0	0
Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 41,222,270 and 34,944,150 shares as of March 31, 2016 and December 31, 2015, respectively	41,222	34,944
Warrants	1,083,193	1,083,193
Additional paid-in capital	226,856,737	175,229,643
Accumulated other comprehensive loss	(1,133,266)	(1,133,266)
Accumulated deficit	(174,216,924)	(168,683,601)
Total stockholders' equity	52,630,962	6,530,913
Total liabilities and stockholders' equity	$ 69,405,552	$ 25,218,472

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred Stock, Shares Authorized	20,000,000	20,000,000
peferred stock, par valur (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, issued shares	41,222,270	34,944,150
Common stock, outstanding shares	41,222,270	34,944,150

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Loss - USD ($)	3 Months Ended
Consolidated Statements of Loss - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Expenses
Research and development	$ 2,689,189	$ 2,708,011
Leukemia & Lymphoma Society funding	(145,249)	(135,747)
General and administrative	2,468,648	1,761,449
Amortization and depreciation	48,347	48,928
Operating loss	(5,060,935)	(4,382,641)
Other income (expenses)
Foreign exchange gain (loss)	(15,984)	9,639
Interest and miscellaneous income	2,329	3,141
Interest expense	(458,733)	(341,122)
Net loss	$ (5,533,323)	$ (4,710,983)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.16)	$ (0.14)
Weighted average of common shares outstanding
Basic and diluted (in shares)	35,400,496	33,704,889

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - 3 months ended Mar. 31, 2016 - USD ($)	Total	Common Stock [Member]	Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 6,530,913	$ 34,944	$ 1,083,193	$ 175,229,643	$ (1,133,266)	$ (168,683,601)
Balance (in shares) at Dec. 31, 2015		34,944,150
Issuance of shares from exercise of stock options and warrants	295,640	$ 324	0	295,316	0	0
Issuance of shares from exercise of stock options and warrants (in share)		324,220
Issued for cash, net of stock issuance costs	50,396,400	$ 5,954	0	50,390,446	0	0
Issued for cash, net of stock issuance costs (in share)		5,953,900
Stock-based compensation	576,070	$ 0	0	576,070	0	0
Stock options granted in payment of accrued bonuses	365,262	0	0	365,262	0	0
Net loss for the period	(5,533,323)	0	0	0	0	(5,533,323)
Balance at Mar. 31, 2016	$ 52,630,962	$ 41,222	$ 1,083,193	$ 226,856,737	$ (1,133,266)	$ (174,216,924)
Balance (in shares) at Mar. 31, 2016		41,222,270

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net loss	$ (5,533,323)	$ (4,710,983)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation	48,347	48,928
Non-cash stock-based compensation expense	576,070	359,200
Non-cash financing costs	112,117	94,664
Changes in operating assets and liabilities
Other receivables	(42,362)	(4,864)
Prepaid expenses and deposits	94,826	79,617
Restricted cash	(6)	(8)
Other current assets	7,861	16,266
Other assets	1,012	0
Accounts payable	(385,118)	46,113
Accrued liabilities	62,979	(285,171)
Deferred rent liability	(2,816)	(2,218)
Deferred revenue	(45,249)	(135,746)
Cash used in operating activities	(5,105,662)	(4,494,202)
Investing activities
Purchase of property and equipment	(3,295)	(17,938)
Cash used in investing activities	(3,295)	(17,938)
Financing activities
Proceeds from issuance of common stock and stock options and warrants exercised	51,105,723	0
Payment of share issuance costs	(413,357)	0
Proceeds from loans payable	0	5,000,000
Repayments of loans payable	(1,296,861)	0
Cash provided by financing activities	49,395,505	5,000,000
Effect of foreign exchange rate changes	1,591	(3,825)
Net change in cash	44,288,139	484,035
Cash and cash equivalents, beginning of period	23,253,328	32,413,777
Cash and cash equivalents, end of period	67,541,467	32,897,812
Supplemental disclosure of cash flow information
Interest paid	356,166	243,750
Stock options granted in payment of accrued bonuses	365,262	0
Common stock issued in payment of accrued bonuses	0	168,843
Warrants issued in connection with debt issuance costs	$ 0	$ 76,897

XML 17 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Liquidity

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Nature of Operations [Text Block]

1.	Nature of Business and Liquidity

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2.	Summary of Significant Accounting Policies

			Deferred
	As Reported		Financing Costs		Adjusted
	December 31, 2015		Reclassification		December 31, 2015
Assets
Other assets	$	460,710	$	(416,712)	$	43,998
Total assets	$	25,635,184	$	(416,712)	$	25,218,472

Loans payable	$	9,497,822	$	(416,712)	$	9,081,110
Total liabilities		19,104,271		(416,712)		18,687,559

Total liabilities and stockholders' equity	$	25,635,184	$	(416,712)	$	25,218,472

All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

3.	Fair Value Measurements

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:

	Fair Value		(Level 1)		(Level 2)		(Level 3)
March 31, 2016
Assets:
Money Market Fund	$	17,194,140	$	17,194,140	$	-	$	-

December 31, 2015
Assets:
Money Market Fund	$	22,162,678	$	22,162,678	$	-	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets

3 Months Ended

Mar. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets [Text Block]

4.	Other Current Assets

Other current assets as of March 31, 2016 and December 31, 2015, consist of the following:

		March 31, 2016			December 31, 2015
Clinical trial materials		$	407,043		$	414,904

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Mar. 31, 2016

Property Plant And Equipment [Abstract]

Property Plant And Equipment Disclosure [Text Block]

5.	Property and Equipment

Property and equipment as of March 31, 2016 and December 31, 2015, including assets held under capital lease, consists of the following:

	March 31, 2016		December 31, 2015
Computer and equipment	$	118,935	$	117,135
Furniture and office equipment		73,863		73,863
Laboratory equipment		1,754,608		1,754,608
Capital lease equipment		155,524		155,524
Leaseholds		56,227		54,732
		2,159,157		2,155,862
Less: Accumulated depreciation		(1,342,719)		(1,294,372)
	$	816,438	$	861,490

During the three months ended March 31, 2016 and March 31, 2015, depreciation and amortization expense was $48,347 and $48,928 respectively.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

3 Months Ended

Mar. 31, 2016

Payables And Accruals [Abstract]

Accounts Payable And Accrued Liabilities Disclosure [Text Block]

6.	Accrued Liabilities

Accrued liabilities as of March 31, 2016 and December 31, 2015 consist of the following:

	March 31, 2016		December 31, 2015
Accrued clinical trial expenses	$	1,042,050	$	1,029,488
Accrued bonuses		254,425		723,039
Accrued salaries and vacation		194,438		202,059
Accrued drug manufacturing expenses		267,802		174,376
Interest payable		114,319		123,867
Accrued other		208,510		124,884
	$	2,081,544	$	2,377,713

XML 23 R13.htm IDEA: XBRL DOCUMENT

Other Liabilities

3 Months Ended

Mar. 31, 2016

Other Liabilities Disclosure [Abstract]

Other Liabilities Disclosure [Text Block]

7.	Other Liabilities

Other non-current liabilities as of March 31, 2016 and December 31, 2015 consist of the following:

	March 31, 2016		December 31, 2015
Non-current income tax liability	$	991,654	$	991,654
Deferred rent		32,523		35,339
	$	1,024,177	$	1,026,993

XML 24 R14.htm IDEA: XBRL DOCUMENT

Loans Payable

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

8.	Loans Payable

Long-term debt as of March 31, 2016 and December 31, 2015, consists of the following:

	March 31, 2016		December 31, 2015

Loan payable	$	13,275,698	$	14,572,558
End of term fee		349,320		303,398
		13,625,018		14,875,956
Deferred debt issuance costs		(350,518)		(416,712)
		13,274,500		14,459,244
Less: Current portion		(436,690)		(5,378,134)
Long-term debt	$	12,837,810	$	9,081,110

The summary of payments due on the term loan as of March 31, 2016, is as follows:

2016	$	436,690
2017		2,603,824
2018		10,827,684
Total loan payments		13,868,198
Less end of term fee		(592,500)
	$	13,275,698

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

9.	Stockholders’ Equity

Public Offering of Common Stock

At-The-Market Equity Offering Program

Warrants

Issue date	Number of warrants		Exercise price		Term	Expiry
December 2011		123,585	$	5.21	7 years	December 2018
February 2012		3,700	$	5.21	6 years	February 2018
June 2012		17,267	$	5.21	7 years	June 2019
August 2012		112,536	$	5.21	7 years	August 2019
April 2013		159,806	$	5.21	7 years	April 2020
April 2013		3,934,649	$	3.58	7 years	April 2020
October 2014		807,777	$	3.58	5 years	October 2019
		5,159,320

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stock Based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10.

Stock Based Compensation

2013 Equity Incentive Plan

The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2016:

				Weighted		Weighted Average Remaining
		Number of options		Average Exercise price		Contractual Life (Yrs)		Aggregate Intrinsic Value

Outstanding at	December 31, 2015		3,944,571	$	2.90
	Granted		1,599,024		1.32
	Exercised		(100,087)		2.25
	Cancelled		(5,334)		2.25
Outstanding at	March 31, 2016		5,438,174	$	2.45		8.1	$	46,686,011

Exercisable at	March 31, 2016		2,488,458	$	2.73		7.1	$	20,650,985

During the three months ended March 31, 2016, 12,081 shares were withheld to satisfy the exercise of certain stock options exercised during the period.

The following table provides information regarding stock options activity for the three months ended March 31, 2016 and 2015:

	Three months ended
	March 31
	2016			2015
Stock compensation expense recognized	$	576,070		$	359,200
Weighted average grant-date fair value of stock options issued (per share)	$	1.03		$	2.31
Grant-date fair value of stock options issued	$	1,651,472		$	1,360,094
Volatility		98.8	%		106.9	%
Risk-free interest rate		1.7	%		1.7	%
Dividend yield		0	%		0	%
Expected life in years		5.9			6.2
Intrinsic value of stock options exercised	$	669,582		$	-

XML 27 R17.htm IDEA: XBRL DOCUMENT

Geographic Segment Information

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

11.

Geographic Segment Information

	Total Assets
	March 31, 2016		December 31, 2015
United States	$	68,531,389	$	24,256,629
Canada		156,905		204,283
Germany		717,258		757,560
Total Assets	$	69,405,552	$	25,218,472

	Net Loss
	Three months ended
	March 31
	2016		2015
United States	$	(5,199,096)	$	(4,311,341)
Canada		(334,227)		(399,642)
Total Net Loss	$	(5,533,323)	$	(4,710,983)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

12.

Commitments and Contingencies

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Use of Estimates, Policy [Policy Text Block]

New Accounting Pronouncements, Policy [Policy Text Block]

			Deferred
	As Reported		Financing Costs		Adjusted
	December 31, 2015		Reclassification		December 31, 2015
Assets
Other assets	$	460,710	$	(416,712)	$	43,998
Total assets	$	25,635,184	$	(416,712)	$	25,218,472

Loans payable	$	9,497,822	$	(416,712)	$	9,081,110
Total liabilities		19,104,271		(416,712)		18,687,559

Total liabilities and stockholders' equity	$	25,635,184	$	(416,712)	$	25,218,472

All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements.

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

The following table summarizes the cumulative effect of the change on total assets, total liabilities and stockholders’ equity in the statement of financial position as of the beginning of the period presented. The adoption of the guidance did not have any effect on loss from operations, and loss per share amounts for the current period and any prior periods.

			Deferred
	As Reported		Financing Costs		Adjusted
	December 31, 2015		Reclassification		December 31, 2015
Assets
Other assets	$	460,710	$	(416,712)	$	43,998
Total assets	$	25,635,184	$	(416,712)	$	25,218,472

Loans payable	$	9,497,822	$	(416,712)	$	9,081,110
Total liabilities		19,104,271		(416,712)		18,687,559

Total liabilities and stockholders' equity	$	25,635,184	$	(416,712)	$	25,218,472

- Definition

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

+ Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value, by Balance Sheet Grouping [Table Text Block]

The Company recognizes transfers between input levels as of the actual date of event. There were no transfers between levels and the following table provides the assets carried at fair value:

	Fair Value		(Level 1)		(Level 2)		(Level 3)
March 31, 2016
Assets:
Money Market Fund	$	17,194,140	$	17,194,140	$	-	$	-

December 31, 2015
Assets:
Money Market Fund	$	22,162,678	$	22,162,678	$	-	$	-

XML 32 R22.htm IDEA: XBRL DOCUMENT

Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2016

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Current Assets [Table Text Block]

Other current assets as of March 31, 2016 and December 31, 2015, consist of the following:

		March 31, 2016			December 31, 2015
Clinical trial materials		$	407,043		$	414,904

XML 33 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2016

Property Plant And Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment as of March 31, 2016 and December 31, 2015, including assets held under capital lease, consists of the following:

	March 31, 2016		December 31, 2015
Computer and equipment	$	118,935	$	117,135
Furniture and office equipment		73,863		73,863
Laboratory equipment		1,754,608		1,754,608
Capital lease equipment		155,524		155,524
Leaseholds		56,227		54,732
		2,159,157		2,155,862
Less: Accumulated depreciation		(1,342,719)		(1,294,372)
	$	816,438	$	861,490

XML 34 R24.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2016

Payables And Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of March 31, 2016 and December 31, 2015 consist of the following:

	March 31, 2016		December 31, 2015
Accrued clinical trial expenses	$	1,042,050	$	1,029,488
Accrued bonuses		254,425		723,039
Accrued salaries and vacation		194,438		202,059
Accrued drug manufacturing expenses		267,802		174,376
Interest payable		114,319		123,867
Accrued other		208,510		124,884
	$	2,081,544	$	2,377,713

XML 35 R25.htm IDEA: XBRL DOCUMENT

Other Liabilities (Tables)

3 Months Ended

Mar. 31, 2016

Other Liabilities Disclosure [Abstract]

Other Noncurrent Liabilities [Table Text Block]

Other non-current liabilities as of March 31, 2016 and December 31, 2015 consist of the following:

	March 31, 2016		December 31, 2015
Non-current income tax liability	$	991,654	$	991,654
Deferred rent		32,523		35,339
	$	1,024,177	$	1,026,993

XML 36 R26.htm IDEA: XBRL DOCUMENT

Loans Payable (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

Long-term debt as of March 31, 2016 and December 31, 2015, consists of the following:

	March 31, 2016		December 31, 2015

Loan payable	$	13,275,698	$	14,572,558
End of term fee		349,320		303,398
		13,625,018		14,875,956
Deferred debt issuance costs		(350,518)		(416,712)
		13,274,500		14,459,244
Less: Current portion		(436,690)		(5,378,134)
Long-term debt	$	12,837,810	$	9,081,110

Schedule of Maturities of Long-term Debt [Table Text Block]

The summary of payments due on the term loan as of March 31, 2016, is as follows:

2016	$	436,690
2017		2,603,824
2018		10,827,684
Total loan payments		13,868,198
Less end of term fee		(592,500)
	$	13,275,698

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The following table summarizes the warrants outstanding to purchase common stock at March 31, 2016:

Issue date	Number of warrants		Exercise price		Term	Expiry
December 2011		123,585	$	5.21	7 years	December 2018
February 2012		3,700	$	5.21	6 years	February 2018
June 2012		17,267	$	5.21	7 years	June 2019
August 2012		112,536	$	5.21	7 years	August 2019
April 2013		159,806	$	5.21	7 years	April 2020
April 2013		3,934,649	$	3.58	7 years	April 2020
October 2014		807,777	$	3.58	5 years	October 2019
		5,159,320

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2016:

				Weighted		Weighted Average Remaining
		Number of options		Average Exercise price		Contractual Life (Yrs)		Aggregate Intrinsic Value

Outstanding at	December 31, 2015		3,944,571	$	2.90
	Granted		1,599,024		1.32
	Exercised		(100,087)		2.25
	Cancelled		(5,334)		2.25
Outstanding at	March 31, 2016		5,438,174	$	2.45		8.1	$	46,686,011

Exercisable at	March 31, 2016		2,488,458	$	2.73		7.1	$	20,650,985

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The following table provides information regarding stock options activity for the three months ended March 31, 2016 and 2015:

	Three months ended
	March 31
	2016			2015
Stock compensation expense recognized	$	576,070		$	359,200
Weighted average grant-date fair value of stock options issued (per share)	$	1.03		$	2.31
Grant-date fair value of stock options issued	$	1,651,472		$	1,360,094
Volatility		98.8	%		106.9	%
Risk-free interest rate		1.7	%		1.7	%
Dividend yield		0	%		0	%
Expected life in years		5.9			6.2
Intrinsic value of stock options exercised	$	669,582		$	-

XML 39 R29.htm IDEA: XBRL DOCUMENT

Geographic Segment Information (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets.

	Total Assets
	March 31, 2016		December 31, 2015
United States	$	68,531,389	$	24,256,629
Canada		156,905		204,283
Germany		717,258		757,560
Total Assets	$	69,405,552	$	25,218,472

	Net Loss
	Three months ended
	March 31
	2016		2015
United States	$	(5,199,096)	$	(4,311,341)
Canada		(334,227)		(399,642)
Total Net Loss	$	(5,533,323)	$	(4,710,983)

XML 40 R30.htm IDEA: XBRL DOCUMENT

Nature of Business and Liquidity (Details Textual) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Nature Of Business And Liquidity [Line Items]
Accumulated deficit	$ (174,216,924)	$ (168,683,601)
Cash and Cash Equivalents, at Carrying Value	$ 67,541,467	$ 23,253,328	$ 32,897,812	$ 32,413,777

XML 41 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Assets
Other assets	$ 43,024	$ 43,998
Total assets	69,405,552	25,218,472
Loans payable	12,837,810	9,081,110
Total liabilities	16,774,590	18,687,559
Total liabilities and stockholders' equity	$ 69,405,552	25,218,472
Scenario, Previously Reported [Member]
Assets
Other assets		460,710
Total assets		25,635,184
Loans payable		9,497,822
Total liabilities		19,104,271
Total liabilities and stockholders' equity		25,635,184
Restatement Adjustment [Member]
Assets
Other assets		(416,712)
Total assets		(416,712)
Loans payable		(416,712)
Total liabilities		(416,712)
Total liabilities and stockholders' equity		$ (416,712)

XML 42 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Assets:
Money Market Fund	$ 17,194,140	$ 22,162,678
Fair Value, Inputs, Level 1 [Member]
Assets:
Money Market Fund	17,194,140	22,162,678
Fair Value, Inputs, Level 2 [Member]
Assets:
Money Market Fund	0	0
Fair Value, Inputs, Level 3 [Member]
Assets:
Money Market Fund	$ 0	$ 0

XML 43 R33.htm IDEA: XBRL DOCUMENT

Other Current Assets (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Other Current Assets [Line Items]
Clinical trial materials	$ 407,043	$ 414,904

XML 44 R34.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,159,157	$ 2,155,862
Less: Accumulated depreciation	(1,342,719)	(1,294,372)
Property and equipment, net	816,438	861,490
Computer and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	118,935	117,135
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	73,863	73,863
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,754,608	1,754,608
Capital lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	155,524	155,524
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 56,227	$ 54,732

XML 45 R35.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
Property and Equipment (Details Textual) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation And Amortization	$ 48,347	$ 48,928

XML 46 R36.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Line Items]
Accrued clinical trial expenses	$ 1,042,050	$ 1,029,488
Accrued bonuses	254,425	723,039
Accrued salaries and vacation	194,438	202,059
Accrued drug manufacturing expenses	267,802	174,376
Interest payable	114,319	123,867
Accrued other	208,510	124,884
Accrued liabilities	$ 2,081,544	$ 2,377,713

XML 47 R37.htm IDEA: XBRL DOCUMENT

Other Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Other Non Current Liabilities [Line Items]
Non-current income tax liability	$ 991,654	$ 991,654
Deferred rent	32,523	35,339
Other non-current liabilities	$ 1,024,177	$ 1,026,993

XML 48 R38.htm IDEA: XBRL DOCUMENT

Loans Payable (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Loan payable	$ 13,275,698	$ 14,572,558
End of term fee	349,320	303,398
Long-term Debt, Gross	13,625,018	14,875,956
Deferred debt issuance costs	(350,518)	(416,712)
Total loan payments	13,274,500	14,459,244
Less: Current portion	(436,690)	(5,378,134)
Long-term debt	$ 12,837,810	$ 9,081,110

XML 49 R39.htm IDEA: XBRL DOCUMENT

Loans Payable (Details 1)	Mar. 31, 2016 USD ($)
Debt Instrument [Line Items]
2016	$ 436,690
2017	2,603,824
2018	10,827,684
Total loan payments	13,868,198
Less end of term fee	(592,500)
Long-term debt	$ 13,275,698

XML 50 R40.htm IDEA: XBRL DOCUMENT

Loans Payable (Details Textual) - USD ($)		1 Months Ended	3 Months Ended
Loans Payable (Details Textual) - USD ($)	May. 09, 2014	Mar. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Amortization Of Financing Costs And Discounts			$ 112,117	$ 94,664
Proceeds From Issuance Of Debt			$ 0	$ 5,000,000
Hercules Technology Growth Capital [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	$ 10,000,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 15,000,000
Long-term Debt, Maturities, Repayment Terms	repayable in installments over forty-eight months and, at drawdown date, had an interest-only period of eighteen months after closing
Line of Credit Facility, Interest Rate Description	Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the U.S. prime rate with interest only period until December 1, 2015.
Line of Credit Facility, Interest Rate During Period			10.00%	9.75%
Proceeds From Issuance Of Debt		$ 5,000,000
Hercules Technology Growth Capital [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Amortization Of Financing Costs And Discounts			$ 66,194	$ 50,518
Deferred Finance Costs, Noncurrent, Net			$ 350,518
Hercules Technology Growth Capital [Member] \| Warrant [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues			210,675
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.67
Debt Issuance Cost			$ 397,649
Warrants Maturity Term			5 years
Hercules Technology Growth Capital [Member] \| Term Loans [Member]
Debt Instrument [Line Items]
Debt Issuance Cost			$ 407,253
Hercules Technology Growth Capital [Member] \| End of Term Fees [Member]
Debt Instrument [Line Items]
Amortization Of Financing Costs And Discounts			45,923	$ 44,146
Debt Issuance Cost			$ 592,500

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details)	3 Months Ended
Stockholders' Equity (Details)	Mar. 31, 2016 $ / shares shares
Class of Warrant or Right, Outstanding	5,159,320
December 2011 [Member]
Class of Warrant or Right, Outstanding	123,585
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	December-2018
February 2012 [Member]
Class of Warrant or Right, Outstanding	3,700
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 5.21
Warrants Maturity Term	6 years
Warrants Expiry Period	February-2018
June 2012 [Member]
Class of Warrant or Right, Outstanding	17,267
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	June 2019
August 2012 [Member]
Class of Warrant or Right, Outstanding	112,536
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	August-2019
April 2013 [Member]
Class of Warrant or Right, Outstanding	159,806
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	April-2020
April 2013 One [Member]
Class of Warrant or Right, Outstanding	3,934,649
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 3.58
Warrants Maturity Term	7 years
Warrants Expiry Period	April-2020
October 2014 [Member]
Class of Warrant or Right, Outstanding	807,777
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 3.58
Warrants Maturity Term	5 years
Warrants Expiry Period	October-2019

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Mar. 29, 2016	Oct. 16, 2015	Mar. 31, 2016	Mar. 31, 2015
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 50,396,400
Proceeds From Issuance Of Common Stock			$ 51,105,723	$ 0
Class of Warrants, Exercises in Period			321,384
Class of Warrants, Expired in Period, Weighted Average Exercise Price			$ 11.25
Class of Warrants, Expired in Period			12,445
Warrants Or Rights Exercises In Period Weighted Average Exercise Price			$ 2.99
Common Stock [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 5,954
Stock Issued During Period, Shares, New Issues			5,953,900
Warrant [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 0
Shares Withheld To Satisfy Exercise Of Certain Warrants Exercised			85,170
Controlled Equity Offering Sales Agreement [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 10,100,000
Commission Percentage On Gross Proceeds		3.00%
Stock Issued During Period, Shares, New Issues			1,353,900
Shares Issued, Price Per Share			$ 7.43
Proceeds From Issuance Of Common Stock			$ 9,800,000
Maximum Common Stock Available To Be Sold		$ 20,000,000
Remaining Common Stock Available To Be Sold			$ 7,900,000
Public Offering [Member]
Schedule Of Shareholders Equity [Line Items]
Proceeds From Issuance Of Common Stock	$ 40,600,000
Public Offering [Member] \| Common Stock [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues	$ 43,700,000
Stock Issued During Period, Shares, New Issues	4,600,000
Shares Issued, Price Per Share	$ 9.50
Public Offering [Member] \| Common Stock [Member] \| Over-Allotment Option [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues	600,000

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details) - Stock Option [Member]	3 Months Ended
	Mar. 31, 2016 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options, Beginning balance \| shares	3,944,571
Number of options, Granted \| shares	1,599,024
Number of options, Exercised \| shares	(100,087)
Number of options, Cancelled \| shares	(5,334)
Number of options, Ending balance \| shares	5,438,174
Number of options, Exercisable \| shares	2,488,458
Weighted Average Exercise price, Beginning balance (in dollars per share) \| $ / shares	$ 2.90
Weighted Average Exercise price, Granted (in dollars per share) \| $ / shares	1.32
Weighted Average Exercise price, Exercised (in dollars per share) \| $ / shares	2.25
Weighted Average Exercise price, Cancelled (in dollars per share) \| $ / shares	2.25
Weighted Average Exercise price, Ending balance (in dollars per share) \| $ / shares	2.45
Weighted Average Exercise price, Exercisable (in dollars per share) \| $ / shares	$ 2.73
Weighted Average Remaining Contractual Life (Yrs), Outstanding (in years)	8 years 1 month 6 days
Weighted Average Remaining Contractual Life (Yrs), Exercisable (in years)	7 years 1 month 6 days
Aggregate Intrinsic Value, outstanding (in dollars) \| $	$ 46,686,011
Aggregate Intrinsic Value, Exercisable (in dollars) \| $	$ 20,650,985

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details 1) - USD ($)	3 Months Ended
Stock Based Compensation (Details 1) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense recognized	$ 576,070	$ 359,200
Weighted average grant-date fair value of stock options issued (per share)	$ 1.03	$ 2.31
Grant-date fair value of stock options issued	$ 1,651,472	$ 1,360,094
Volatility	98.80%	106.90%
Risk-free interest rate	1.70%	1.70%
Dividend yield	0.00%	0.00%
Expected life in years	5 years 10 months 24 days	6 years 2 months 12 days
Intrinsic value of stock options exercised	$ 669,582	$ 0

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
Stock Based Compensation (Details Textual) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total		397,024	60,517
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures, Total	$ 365,262	$ 365,262	$ 168,843
Shares Withheld to Satisfy Exercise of Certain Stock Options Exercised	12,081
Non vested Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 4,850,285
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months

XML 56 R46.htm IDEA: XBRL DOCUMENT

Geographic Segment Information (Details) - USD ($)	3 Months Ended
Geographic Segment Information (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$ 69,405,552		$ 25,218,472
Total Net Loss	(5,533,323)	$ (4,710,983)
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	68,531,389		24,256,629
Total Net Loss	(5,199,096)	(4,311,341)
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	156,905		204,283
Total Net Loss	(334,227)	$ (399,642)
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$ 717,258		$ 757,560

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 57 R47.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Jun. 30, 2013
Loss Contingencies [Line Items]
Restricted Investments	$ 120,000
Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Agreement termination notice period	90 days
Rectification of default period	60 days
Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	50.00%
Leukemia & Lymphoma Society Agreement [Member] \| Phase 3 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	$ 5,000,000
Leukemia & Lymphoma Society Agreement [Member] \| Phase 2 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	4,100,000
Vancouver Laboratory Space, British Columbia [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	159,700
Ewing, New Jersey [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	$ 322,000
Letters of Credit Outstanding, Amount		$ 200,000
British Columbia Cancer Agency [Member]
Loss Contingencies [Line Items]
Rectification of default period	45 days
Minimum [Member] \| Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	45.00%
Minimum [Member] \| Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	1.5
Maximum [Member] \| Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	55.00%
Maximum [Member] \| Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	3.55
Percentage Of Cash Payment Or Loyalties	5.00%

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 104 189 1 false 43 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.celatorpharma.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.celatorpharma.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Consolidated Balance Sheets [Parenthetical] Sheet http://www.celatorpharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Consolidated Statements of Loss Sheet http://www.celatorpharma.com/role/ConsolidatedStatementsOfLoss Consolidated Statements of Loss Statements 4 false false R5.htm 105 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.celatorpharma.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.celatorpharma.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 107 - Disclosure - Nature of Business and Liquidity Sheet http://www.celatorpharma.com/role/NatureOfBusinessAndLiquidity Nature of Business and Liquidity Notes 7 false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.celatorpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 110 - Disclosure - Other Current Assets Sheet http://www.celatorpharma.com/role/OtherCurrentAssets Other Current Assets Notes 10 false false R11.htm 111 - Disclosure - Property and Equipment Sheet http://www.celatorpharma.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 112 - Disclosure - Accrued Liabilities Sheet http://www.celatorpharma.com/role/AccruedLiabilities Accrued Liabilities Notes 12 false false R13.htm 113 - Disclosure - Other Liabilities Sheet http://www.celatorpharma.com/role/OtherLiabilities Other Liabilities Notes 13 false false R14.htm 114 - Disclosure - Loans Payable Sheet http://www.celatorpharma.com/role/LoansPayable Loans Payable Notes 14 false false R15.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.celatorpharma.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 116 - Disclosure - Stock Based Compensation Sheet http://www.celatorpharma.com/role/StockBasedCompensation Stock Based Compensation Notes 16 false false R17.htm 117 - Disclosure - Geographic Segment Information Sheet http://www.celatorpharma.com/role/GeographicSegmentInformation Geographic Segment Information Notes 17 false false R18.htm 118 - Disclosure - Commitments and Contingencies Sheet http://www.celatorpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 120 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 121 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.celatorpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.celatorpharma.com/role/FairValueMeasurements 21 false false R22.htm 122 - Disclosure - Other Current Assets (Tables) Sheet http://www.celatorpharma.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.celatorpharma.com/role/OtherCurrentAssets 22 false false R23.htm 123 - Disclosure - Property and Equipment (Tables) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.celatorpharma.com/role/PropertyAndEquipment 23 false false R24.htm 124 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.celatorpharma.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.celatorpharma.com/role/AccruedLiabilities 24 false false R25.htm 125 - Disclosure - Other Liabilities (Tables) Sheet http://www.celatorpharma.com/role/OtherLiabilitiesTables Other Liabilities (Tables) Tables http://www.celatorpharma.com/role/OtherLiabilities 25 false false R26.htm 126 - Disclosure - Loans Payable (Tables) Sheet http://www.celatorpharma.com/role/LoansPayableTables Loans Payable (Tables) Tables http://www.celatorpharma.com/role/LoansPayable 26 false false R27.htm 127 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.celatorpharma.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.celatorpharma.com/role/StockholdersEquity 27 false false R28.htm 128 - Disclosure - Stock Based Compensation (Tables) Sheet http://www.celatorpharma.com/role/StockBasedCompensationTables Stock Based Compensation (Tables) Tables http://www.celatorpharma.com/role/StockBasedCompensation 28 false false R29.htm 129 - Disclosure - Geographic Segment Information (Tables) Sheet http://www.celatorpharma.com/role/GeographicSegmentInformationTables Geographic Segment Information (Tables) Tables http://www.celatorpharma.com/role/GeographicSegmentInformation 29 false false R30.htm 130 - Disclosure - Nature of Business and Liquidity (Details Textual) Sheet http://www.celatorpharma.com/role/NatureOfBusinessAndLiquidityDetailsTextual Nature of Business and Liquidity (Details Textual) Details http://www.celatorpharma.com/role/NatureOfBusinessAndLiquidity 30 false false R31.htm 131 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.celatorpharma.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 132 - Disclosure - Fair Value Measurements (Details) Sheet http://www.celatorpharma.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.celatorpharma.com/role/FairValueMeasurementsTables 32 false false R33.htm 133 - Disclosure - Other Current Assets (Details) Sheet http://www.celatorpharma.com/role/OtherCurrentAssetsDetails Other Current Assets (Details) Details http://www.celatorpharma.com/role/OtherCurrentAssetsTables 33 false false R34.htm 134 - Disclosure - Property and Equipment (Details) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.celatorpharma.com/role/PropertyAndEquipmentTables 34 false false R35.htm 135 - Disclosure - Property and Equipment (Details Textual) Sheet http://www.celatorpharma.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://www.celatorpharma.com/role/PropertyAndEquipmentTables 35 false false R36.htm 136 - Disclosure - Accrued Liabilities (Details) Sheet http://www.celatorpharma.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.celatorpharma.com/role/AccruedLiabilitiesTables 36 false false R37.htm 137 - Disclosure - Other Liabilities (Details) Sheet http://www.celatorpharma.com/role/OtherLiabilitiesDetails Other Liabilities (Details) Details http://www.celatorpharma.com/role/OtherLiabilitiesTables 37 false false R38.htm 138 - Disclosure - Loans Payable (Details) Sheet http://www.celatorpharma.com/role/LoansPayableDetails Loans Payable (Details) Details http://www.celatorpharma.com/role/LoansPayableTables 38 false false R39.htm 139 - Disclosure - Loans Payable (Details 1) Sheet http://www.celatorpharma.com/role/LoansPayableDetails1 Loans Payable (Details 1) Details http://www.celatorpharma.com/role/LoansPayableTables 39 false false R40.htm 140 - Disclosure - Loans Payable (Details Textual) Sheet http://www.celatorpharma.com/role/LoansPayableDetailsTextual Loans Payable (Details Textual) Details http://www.celatorpharma.com/role/LoansPayableTables 40 false false R41.htm 141 - Disclosure - Stockholders' Equity (Details) Sheet http://www.celatorpharma.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.celatorpharma.com/role/StockholdersEquityTables 41 false false R42.htm 142 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.celatorpharma.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.celatorpharma.com/role/StockholdersEquityTables 42 false false R43.htm 143 - Disclosure - Stock Based Compensation (Details) Sheet http://www.celatorpharma.com/role/StockBasedCompensationDetails Stock Based Compensation (Details) Details http://www.celatorpharma.com/role/StockBasedCompensationTables 43 false false R44.htm 144 - Disclosure - Stock Based Compensation (Details 1) Sheet http://www.celatorpharma.com/role/StockBasedCompensationDetails1 Stock Based Compensation (Details 1) Details http://www.celatorpharma.com/role/StockBasedCompensationTables 44 false false R45.htm 145 - Disclosure - Stock Based Compensation (Details Textual) Sheet http://www.celatorpharma.com/role/StockBasedCompensationDetailsTextual Stock Based Compensation (Details Textual) Details http://www.celatorpharma.com/role/StockBasedCompensationTables 45 false false R46.htm 146 - Disclosure - Geographic Segment Information (Details) Sheet http://www.celatorpharma.com/role/GeographicSegmentInformationDetails Geographic Segment Information (Details) Details http://www.celatorpharma.com/role/GeographicSegmentInformationTables 46 false false R47.htm 147 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.celatorpharma.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.celatorpharma.com/role/CommitmentsAndContingencies 47 false false All Reports Book All Reports cpxx-20160331.xml cpxx-20160331.xsd cpxx-20160331_cal.xml cpxx-20160331_def.xml cpxx-20160331_lab.xml cpxx-20160331_pre.xml true true ZIP 64 0001144204-16-100409-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-100409-xbrl.zip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
K&""L3'Q2V]#O\"( Y.S#&MK7-\1R9\< M(^.PX!%SCSSEV;X,82?:7PGXY.G#-,!'U(0B)18.]MB@Z87E3=9L0P)M4UC: MQ52,\R&/$1'^P(^ M)_F^3 \/<)<7R(Y*JZF8DWH[3"BDD9\I3D2@I@J@\HKM1,F.&&:SY.<%DM$M MC8S ZPLBY65&]X70U4N<[I^?*?>YHP6[M>**F\)#B7RR!*<\Y:@U/S@)8'@RD193TW MF@_O#@):D'4L#X&ZMU!4[TB$KZ'OPLN M!EU[D6M$ZB%<7"N-].'!T872"B0/8A=A.UE\/+7-3(U>'E<:/6) $T*)7'GT MB+1(KO< $N/I,"B4.W( 2:=ZTR9/E[ HKW[=FP20&!([AHVA1-*;LP6K!L8H M 24-R?I835H;4_8SYB4H4E]8E&_K,R!27H*S$0[IWQ!I1UH1">DW'^WB&1;S M-,V)%Y-6D]-ZI!4T[D/"%?QSNR#4]NS8F%4>#,@9K9T++NK:;"(&+&,7:526 MB]7I'(OV[4F)K^75WA0]G=O%RT".+EH("3Y\U43X)I*1X< ._UZ7'D+AHV6T M7AO!*;ZU:JE-0D^]FLQ8]#,( M82E]3\4.5V\EBZEP":5"A;^ "E%GH2OCNM3*GY!AVL!T^9A_0A-5K@ZU\BU6 M%["HT"FI6?.Z_E&J+@,[]>"4&S "0J]=">H.L9UG79Y62@1:UFN[%ONQA5=U M''M$VMK:6 OK\2G9^&"%+5M/) +>%(^B.;Q[=!RU&>'J?E$\X/68W[CWV5$/ M[-1/,$#?$9!P*0'MLG&=OZ@4XY(WUZ".BV5NS%1W4#NOCOKHV'AN8H7UW MAJ@K9A62HA''D&&C0IKZMA*C:),PLF$$57*P;^@>_P?O&00=AKE?$$FNVRL\ M"O8*B]->H1%^](JV"28#8;5%J/7\E6P I"K0:_&7X!])3T?C%O6,_AO]%_H' M#ITEP_/_ %!+ P04 " !H@*I(,O0>G_LW #4NP, %0 &-P>'@M,C Q M-C S,S%?<')E+GAM;.U]6W/CN)+F^T;L?ZBI>:XN2;Z5.T[OA*]U/..R'+:[ M>T]L;#!H"I)PFB+5O+BLL['_?1*D9%,2KB0HI-CUTN6V 1!??HE;(C/QM_]X MG84?7DB2TCCZY6/_I]['#R0*XA&-)K]\_/7I^M.7CQ_^XW_]S__QMW_[].G# M5Q*1Q,_(Z,/SXL.EG_E/B1_\D:[J?^C_U/_I] /[H??IF[_X-.CUCS_\G][! MS[V3GWNG__?#_SO[]O\_7#T^??CTX?OW[S^-H(6L:.&G()Y]^/2)?2>DT1_/ M?DH^0,>B])>/TRR;__SY,RO_^IR$/\7)Y/.@USOXO"KXL2SY\VM*UTI_/UB5 M[7_^W]]N'X,IF?F?:)1F?A2\UV+-\.KU3T]//Q=_A:(I_3DMZM_&@9\5HE+V MZX.P!/N_3ZMBG]BO/O4'GP[Z/[VFHX\@@P\?_I;$(7D@XP]%!W[.%G/RR\>4 MSN8AZWCQNVE"QK]\#.:OKX68>P=E_7^_C(-\1J+L+!I=11G-%C?1.$YF1:\_ M?F#M_OIPL];]@(1^%B?SJ0_%&!.?6:G/\H8^0S\;]G2834ERD2<)^TB:DBPU MZA^ONH5>W2?QG"39@L'^,Z=S)@*C?O$;L-"SLR!(-5M ML5BW3]N5+?3H-O:C]-Y?^,^LK$%OUBM:Z,EC%@=_3.-P!/,CTX5L8=0?7G5; MO3J'J6=T$<_F)$K-YP91$Q9Z]Y7$D\2?3VGP2"9L[-2=O^0-6>@I0)_1C+6< MPEB_B&&2C":P>)H. FD[5OH9I7%(1VSA/O=#MOH]3HGI="MIQ89.YK.9GRR& MXTB8!CY,ZD$0YX4P[N'#3!RK?\UTU;#IG:%Y8O-,&UA6#5M D;MWX[_>HW[5B_K9[5 M&PUMTJIV?)>M?] M)%@U#C]N$;KN>[$L\7E>F-8^!5,:ONG".(EG-:2Z[$NL!RI/H7OQG/V.S;9Q M NO>+Q]ASP$0QR1)X(A92D@(H>A_(<9FC([]]+EH-4\_37Q_SF@]^DS"+%W] MAO%[5.%W^6OO;1:^"/UTM82?O=*40[*RCM?O'1RY)%O%V#J_NGCX/ _VBN M=;#P"3W< T*?H%D%@:R(AW&"7:- 3-JJ_WR2CA"3= ;='S$(UZ$_$;"T5L9S M.EO6HVD+ )^G8\0\K4#?DX3&L-<;7<)RH1A5:V6]D_WC30B$S]_)'O!W3=/ M#_]!_.0:?J-:V#9*>U_VET,.%#Z+7_:&Q5(M]7FLE/=.]YW)#3!\+D\1 MEQ_(A+)C!.-R.M_D864P(VR M7K^_KPSRD @H=&&UT:5PZ:SROC3(]S6BXEY_L']$2L$(N'1AF3$;CMCLVA4]'/I M@0K+6QBS&U#)_:"EEKU!P^O#^C+A1.4 R>?PQ3\D>"6UO('3!=$F(_R+"Q5V M2U>0+R1YCE-RZW#4?,5S[/@$['XF<[ (NQF'I?LQ\KHH.^6&J,P+%M;S!%U=C M;^E_M7*I7G5N/03!:!C6;-$;.#6HZK+$'XM-,'=@6&XEV' P*+>B/4SVK>K* MWNGQL=.]:>WQJ%$;P#F]6S2E0;(AU0':@1&WED3&R1'R.3,\&?(J> =]5X-J MO4,Z TE0PSMP:KO6$#!_N,C@=&"$< (^'(R3\LL:XV.]H'?2=[8CW!;<79P1 MLZ&BW08 1;'MXXF?/VP,H75E)&VGX7*QZKQ)>3BN]N6!=7QIXRJ,QRSEX0B6 MQS(426-U:M2P=W#H;!73[?AYM>-:JUVSECVWWO86B16LGA;$TX&Y09K^SL$, ML>S% YG'"0LJTQC[HBK>P8FS)7BC2X:+K[JV=^#4#U%+](+E5Q-,=]EP-0JU^ZHQ'LX:\0Z<^;?59XH_7&N [,71%:4Q=K(FK MN+3A^)I&T!?JA_=Q2A4QOR;5O4.'Q]5E]T3QO_R"WB&*V<$6'T2U,/R)_ M-Z,OCYRZ>4NH4G#*!?(CX#?RCE"LD'*>!*LA'PR>4%\+8_96$O(K+NP=H;"B MFX_2=01X8GP;N 04SEP:.X/U@MX1"H_MM!)8"@#.2K#FMN:)QY:"G MR^9&>>_(J9>XA"<9H3P0E@*&W?/*$E*QHQ3\P^X?7ORP.%QE%WZ2+.!P520M MDBVH.O6](Q3F6S&=@O55&YNE^&/WZO! 0"HT8#;GAHIAV))WA,*%TE1%ZJ"T M%.;L7EE6?FHKM^\'$A SAS>[DBV%**&;Y^TOG>$PIG(5#'TL5F*E':O#LL@ M@*M7=GU%5J**1G=Q%"AU05W9.T)QRV"J")K ; 5#;[!C3J@?IH_Y?!Y2 M\C8$).P+ZWC'*,PMIJ3+\=B*S';/]9I<=$\#WC$*BXOQC+Z%P594=A9G?NAX MZA9$?\!:52=&!JIYQRA,,-IG/2466V'<[D=M)49/:VWFEO>.41AHM/D5@[ 5 M].V>V-63LHIYV#O>1S-,T6M;8=ONI]Q*:(&&.8U3VCM&850QLI"*8 AHW4-[ M6@6AOK%47,D[1F$6$?&F9)D'1T#V'EK+;N-H\D22&0M^4&^".:4]')%2"L($ M+ O@".C=8_O6,C)*WZ"U7L$[1F&XJ$6R!)& YSTT7&U'UVI1S:_C':-P!:K+ MM@24P%ED#TU4JS0F#^2%1+G&P.97\$Y0&*=J42U!).!Y#\U31B.:H_4G* Q5 M]59G/AH!MWMHLMJ,S]:W9' K>:<'V.9MC9VV"H^ [CVT6:UVFVNAZNJ]=K6X M=X3#\&QXF!(B$9!K;+?:SHGE=*;6FZ*]$Q36C]H'XZ+_ @;WT)JU'<>L%0L@ MJN2=H#![&-FV%&@$7.^AB>M^U=\"L\$A:6C%K%<+ )6]]"6];N?L 3_S!'A@4ZFF2)!L$XU[P3%CKD6 MVTI< N;WT;HU&M$2QKU/1S?1,FVKS+;%K^%]06'NJ,6W#)(@7F8/[5IG09#/ M\B)E1)E/-YX!A"F)4OI";J(@GI';.&4.B,/QD_\J-V^:M.1]07&RJJ<:-: * M5&8/360/["7MB(RN_"2"N2^M2..2C&E 91MX=67O"PHOH%J*H8E.H OF)C7G MNK M)5#_,!\5SVDG!659EM#G/&-&B*>869OB*(/>0U% UHD0C3JH]/;\87E7O"PI7I]I.,D), O;-G=8V MV-]]/KA\-O.3Q7#\2"<1A6F5N5^6M\[%H @IR^ZQ^M=%QHOMWNC$/PHK>8<' M[H[VJT0BPKX5>RAEQ->\0Q0!3B%MTY%?@ZD+VBU]3,AQ?I1F=P10D,ZZO M%_0.4=C7:_'*0=*%1!=WY'M%'$D.'MRYC&8DE$>PJPC4386'#SUHPE);Z)J&1H%= X<:"5C MM/HA[_04Q46,BE3!4:H%670@6=RU3Y/B N,;\5DVO#)3K+-1_M:=]_Q\.N-< M5LW[XNSMC+=NG2^JB?B^)G$^I\Q/0SV$=9OP3G'D/%8RP1^=9C [,.XX#]@Y M&W1XGV0\=?8DX_MR(6#*;/U5-0)ZC6'TVN!+M?QJB:+;[S>Z&^KMON)XBN\5 MQT9O-U:?;L(P//48$'DB:8'LP-*Z'9;B<+Q9?ZWQ]-3]DBB0L-F2J&K$Z_=0 M.)"HR%"M=WHXN[/@;089N!M\[;_*Z"SQ>-&[]_"-.B-1MPF B<)Q3Y<0_G@T M0]N!5; : .+R:&GGJ<9^#\%)D/6MQD*W70W@(#GNB86M6M9$J+IP"?J.\IN? MY4DQ30S'U0P&-=1 KRF8?U"XP#51#1.D]F]:=W]SMN5RXVZ^K?WDY\#94T?O M>L-_W7+E>S],2M=[LU%GV"8( H5K,H\>U;"K!;4#.QW^$Z$.]SQ('PKM]Q#< M>+\_2UE%4% X++0P/0LR^K*:1 T'>\W&030H['LV"%;.$HUDU*W=W=8;J6?? M_614E06[DRRU($WS6?F[1HI9_T- KWB]TJ:5-Y=6!_*7S/[[[@:THR&@ V M!RO=+A[WZQ^Z6[5JON[7Q^'^J"]>P7#DH.K$_&_U@;_^(8I9F4>6@E8^E"ZX M/C=]XZ]_B"0Q@90I/KTB.#^>^6-B0W&346.L;F#HPDM_ZZE1BAU?>I9GTSAA M'D=2=PU91:^/[,G5#>I$WAEJ3)8>!T1$.FQ@ATDAJ%'A_'E/D@*Z-OFB!D!@ M*,QX391 CLW2BX(8DKE54ND8S *26B A%'* M^]7:"B '9NE%0)1C_R9-<[-Q7]8 R:"(+&XXYJM@.O/2WQ9*O61BLFH@(13A M+@WIWD+4UKM^.S=:?B7Q)/'G4QH\D@D3T$TTCJ&$VZNY95\>R)QE3XDF.D9* M016OWT/@B;O9NXJ4SQ?+/QI>59BTZ/7[. Y;4I*4MPWFD+OCKGO'G'5 ".=Y M"E-8RMR<;^F?.1W1;'')4EJ%A]PZ6W6._ M\622$]T8Z%6$;J+8OZH$N3ZP3+#AN4=(2?#3)'[Y/"*4J>4A^X&1?5C11OB5 M=TLF?G@%PL@6@KL"3BD ZW17:D+).IE",'CN!W29*Q$([P$VBP!,IUM+H>2W M"=KN=B>L_/ES2O[,0417+VSEA>^I;N?X-;RC Z=W<_5'GQ:P+EP"< J+^R$ M=;S3+SCN[62L:1-=Q>36]%]C_R.[H-.O#.#W= ";8K1DSG/UTRA(KP3_,+?W%#PN'P.S"3Y(%R$#Y;(1.?9 :[IVV MEG880&WM$@!IYKFE+:(+1HC34V=QPW5=&D]/47C.J(0JV%QQL. Q0%@@\S$@ MD9_06->)L5J>I1_ 8%ZP@#R1=#8ZST3_S-&,_*?F7U&)QVCCNQVM1KT;6!5_(QM[,O1XN-S?] MA7L31!?,'V4N0YV3P5I!EC4#A]521 Z?2RZ*SK@H5M)S54H@H.X M7/%IE0'ID-]AB5 Y2!EP%(/3@,&UGEOR(<1 F8TGW4$H*.P8AG.M!(LMAT$4 M#!N_Z@[C )?M0I//+0@"&BTXE#FET?K[;" M7,8,8\)EN 1:8&R]0F#4Y[XK MT2$;?G^ ]E4)Q<*H4QW@X=BX*@C@CS9]A%VX!;@*Z80"(C8+#9,"Y'6BN!G0;L/KXUAP]2GFJX@AX"[<*FR XTA >^4)"#\Z>*6O)!0,9WH-0 "0Q&RUW0N,4';A=L*[M9N&[G^;*+3 M#H@/Q86&"=D*==&'W87;CC>$-]$\S])"5'WE'9>D%H@&19JM&GPJ%$.$M0NW M)#R0@UIJ,'@3#8JC2JMJL(;5TB4+.C4XJ*4&!V^B06&H;U4-UK!:NHW!H0:\ MC==;TL+W/&A^F>A3Y\*\:=,@9!17!?9VITWD8.D>R:VRK<#>1&F6Y.7(7/VN MO#7CR4CK_=F&37O]0V1FE2;*(E!$*S+JTGW7MS@BBV]^\@?)KO-H9! 2H:@) MHD+A&62'^+P?V30_/A+ APE+Q9*\WOH*H' MG41AR[ BZ_71:8 ?S]U+RRD@3IR:*0P86:=2B 7/94AK&2!.G)H4A)+?)FB[ MVVXO( 0SZ?;B)3O"J:H 4*=G_=I#2@]8%^X(OL$)(8%-7OJ8S^=AZ?92 )=M M:D5U0"Q.C^)ZM FVJ7)0EBS["/:GO'?N'>Y0VWWHOO^E[VIDO<\[XA?=5;&] MFDT 3!3'2$T^^ /0#*RE3:G[ 8AV/.%1D(EC=H@+R3!A2;\\G5$&ZZEK2]B M]=#*P*11&^2%PKE#FUI#S=A$:FG;[5XSV)-N.73C#:GR5DY0 ^2"PLJA32%? M Z3H+&W5W;-^G2<19%\T))J+RI*[C7MVR^/JWTDX^A5.=LG2TGM+_%1CD*LK@[10N%XTU %= MH)V)<2Z@L3"D(D_9ZG]N9O,D?BG]5I3*H=L$2 Z%,T5#%3&#:\E!Q[VB"*4F M,^+J5_;ZIRB<'UH]26Z@[T8 M^#DE!6S0ZF[$7-OY5_%XH'-EFQ-(G0/2X+9M:ZF57&HU] M94Y+18S(A/4(YZQT1VH9_J$:" F%O;.E&>D-H:T8]"QFNV><%U(.'[1I]UYJ ML)$1K*/W4@,<>0TU^6AX+S409SG\<2_%L>8/>B@N'LSXK7\O5<#]<2^E?;P? M]'#?2FQ26_]>JD#:F7NIMHT0@QX*"U6KT\8&VL[<7E5//QN''JFKN;"6=W2, M>Y;88)*O!TJ ]N/*=[[+AS-PDD,_WQ-LN70Z*U/S,>MPT2\_U D>D]3R!AMO MT=D)9]@6FF8\@Z B=!/'=:]*DNOCQ 3<7R5:8=!W_^*6)B7K9 K!=#]<8=!W M>O\JE/PV0=O=1AFNL*UVLDVFJ@H =>^^7FM,Z2%S&Z\@I_ "2M+ #Y^8#_[5 MZYQ$*3>YK+*.-T#P^IR2"C%]$E"MQ2 XN8)B8,_C"$"E%\JT[=SR(!6G]]%U MJ-8 U!UWIA+CHQ_Z"35@>:,"2,7I%;,%FKF($/@GR>?DRR2?7+)T-G%QE"VB MCQ53,J^*=WBR=_SI8>K0.PLW$>@12;/ER4P]5OD50"Y.[^N;C%49H@X]SU"F M"BCS-:_>*%B=P]>$)B%?NPV8Z=R_]EI3'PQ!=BGAS39&[<5[NPZ(QZF-UL+Z M+0)E*VV-1W_BQ)_&A2*/_O-)L6!VZ6(Y2E2XZ'XW%* M2FO;3?F^Z8C#N\76088H/,N,M,,Z_J96:43!)5])!)(,FQP.<$2DU>)>B:LSX:YOXBFM&+?R&%=.:9 ' M"BM,+9Z%>*P%L6X8+'=/\%TLHEP+2.!,HZX*P<)EHM,X&FK"L&:V=#_+K M."%T$I4F^6#Q!/N=%& "L*\^C9C6GY,QE'GR7R7:8- *"!"%F4>3:;Z:&..U M%FGJ7&%65[RKW*ZE[#1NN=^A JH!=7QM 4"BR M%AGQ6DLU2J0"E3#V-1V]O2WS-:9'5" MD8,5:-,>6@=_AX/0E VT%]AA3%2(9YEF9^82[7GW?J-0AB16%K M:J05?$5K(A"!GAE;(T6SEINGX7!$0&]UQ>3M-W5E[_2D9^WR[=@X" M!MM^D(3['#1-">:#LA6;[3JNZS;VHU7LHM-GR)\SP]?%>16\P>#$W63XG-U$ MT(]<)Z*+4QHZC^)"429:T1PH -.%@^=M'$U@%IXQD!J);7G%01@H[A.%//%I M%4/IPE%S$YWRN,FOX T.4-P7BLG2([>*I@MQ7>NZ+CN4*FJ 2%"8!@T'KQ1- M%TZ@U9V+=-2^%P/P**[BI-R(ANLF#!3G2'E^H*MHQ#($^-$33#371&B2%Q0' MG"BL>09TJ>%8.A?B./Y7Y7+A)\F"1I.S&#DYC;%(L-AJ@&KI9. MC;NG_M?(+T-#V(-% #M-QW?DSM2575 6$@G C\TZ7#KF; M:'[8*='*/P%#"@48+"5 JR! 53(2:EKDBO'2A'O]!CUG8.8D0T(32W2 MB$R63!9GT>C"GU.F'<1/R? YI)."$]7&7UP1%'??J#8!UE;R+@R&S"=H*P=4 M>VS.'!Q\P7&"KN6<>H!FYR$2K;XYLP"#QYS9\D.PAP@W'!4>UFD3(L!CJVSM M]==#IXN34/+;!&UW&V60XM])$N0A@;4CF$9Q&$\67Y/X>S9=+J+?",LU(-HA M:E4&\$X]"OED<#:+!FBZ8%!\"\"]^C,'X5S$LWD4;Z)270-SR( X4]WL:G/')EJ"R9(YS2O+O/LM9GPEG;FXY@(_B M6D_"#9],#@I+IC"[ZRRS0A1'-OF*NE$, *&XC-.F10S"DBG,+BN%__G20*1@ MAE,4@*&X_3)C1PC$DK>FVTW--$ZRE0U=(Q216]X[[J$8=::;&#$66U8O7-PJ M]R^"&MZQV\=4-0C39+B*QY:39COKGMZRMYR.C@1"HE/).<%JPR.B;!BQ$5J84NDUX M ^3.-6*U,(-H*U^[6Z]?D,MP7"9-N_8#EE]K<>W3Y#<_S.$/9>1T)0>TS)W. ML"F0(FY'$+&BU(-J*R4[.H7YYK_263X[CY,D_LX&C#^'OV0+0V41-0/20YTR MQ%!1Y#!MY5-WJB3+-+I+V_DP>6#YY:]>21+0E-PG-"!O?TR7?TW[$FVIU1[( M$^'^5$MM&N 5N&CLER6NFKRA6'U5IY-J69 #"NM.#=X%6 2<6@B/=I>OMMQ= ME2C?P\'OB$[Z6F%=$!>*"Y-:U&MA$ZC"?IG[%'$([$\-(LJ*ZB MW,$^DCV# M-CR!,NR7#9&W15H]B?C@9^22I$%""Y"&^TE!*][@>%\/J,8H!1JR*XNEX,YF MM759:O>"J;3HYH97%K#MV\E1@47 TW[9'97:63&U-1G*E6:\H^-]W>N9PQ0H MR7Y9(N^3."!DE%Z##%=;W>%8DQ+^X\B*@PM$_C M$+J>EEY$#A/65RK:!W,G"6 NG-!U45+K1>$+J,PDN:)TC1C_PTC?,4NGT5DA>B<.U25/-.W+X-H$,'AT M5):BA%K)R7!- MGI/<3Q85 ,L$-U(V%=4 M].37TTVM5"AR/8C8/,_\X@8,BFI GC=ORQHSJ(2 M$8ID.Z+G /))GF:&'$HK 6:GF\R:+&I@PISKYFR>T+#:^RE-,J):).6U +73 M0W1=)C5 68H*VBF5PT@U+%45 ;O[9SSM$;J!RU(<42N<#H,L7M^V7<>YQ@!5 MU0/D[I]Q-&=4#Y:MZ"$,]]MO)^I;#<_J[<(@210WV&K#@ J#XW"A%AV9]-PA M555!]5&X3XOXX[.MAZH304DXG-A.<&0.LJ E>E =QT6U=6-]XC:OD!F-"AB. MPZ 4%%V]SFFR$-XR"\MZ_9[;+58#CC@X6HADPG-[Z# 18>U+Q#KOJ A4_3&8 MDE$>PB1:1"RM24AT4:A7$;J)\N)P^Z44$SQXL@PV.%?DSRD=43]9//H%8#8V M5,DG1'5 +.X-/IKD"4X=$ H-29*925O1,< MX1$*)@7T:\)#>=%Y$4<9-!N24:GLPS%T!C-X;K-H"A@_CY_#FFPZKR<85Y9@(;#9E"?23&L+B1 9),9^3,'$5Z] M,..91H(H?@T0B?O+M<8KM!!8%_(@<@"JEV51'1 +CL.GC#5MHJN8W&9+M)3G MAIU/R>C>3T#QWZ>Z]'Q1_8LJ@9%V(R XI]Z!S0>_*5:WR1OM*XER(M@N[)T< MH]B/FU*G5H JOD[D@&PEL?7)\;XO^&IXG4@3:2?)]31J?;0FJ;MS\ MQK-9'!5''&6"NZVR( <4T<<2D@07=WPDG;C/K9>W_.08Q8G;F$D.BDZDG'R; ML!X#$OD)C747W6IYD,>>;[ EL#J1I7(%Z]Z1<4MUH2 MT@0LRQ%U(EMEY8RA82[CE/;Z/;>)Y)J/9C&J3F2?-+FXVK8D@R!0I'\3DZ0D M=0U))_)&#E](=A%+H> MS&8T3:%3T/. R7]"AM'7)$[353H2L<>!LBH@QWVLDI)LAM)63D:,0]]ZIO@3 MM^]8M3KXN5@[D::Q1%8B+ISV 7#Q.YE"B.J 7-RGT6BN W)XG4C(R,]+5;$, M2^A7U@4Y.;6GVE$#39@XLR\N\X]7>GOVXM.0[8F?XG/R&(?"N F-JM[IP;[O M ;11.L[:*.#W@;"3:_%NA3G#6I4!_1ZOYZ8X':==%.WDUT+LTE5P77H3R4.? M5/68[6+?![ FQA82++9![)Q"1U9=_YVP8$DR.GLA"1Q-UF(JM2G7;I$):M]' M>F/T C5Q;,:3PZJG"@SP'F_2]1$**-V5W4Z5LW 9$;TU;]49_(T:!7&YS;1M M02%L"$ 01N38F%<>1G^GV71*PM%3_ BLI./%"@ <2$B2P2YG8&*=Y4AZOW[JT="\N M7DDIB'MFG;XO7\A(-:*SFS7L#39\M7?J&;.FY5MLG3'UG!1N)NGYXKW,$L/9 M=S\9*;-)V_H&" I%Z*$-N@460;NBZD2H^LK-:;D7TPI5%]4!L>#(E&V79]$5 M@U0*78AJKR)3.@-M%P9!X/*;YS/%IU<$QVV4NJ65&O;2+\#""WE_!N.!IJIQ M+ZL&PD'A1;^3H:\6A-N(=MM:4D3TP]JJ%38KJ^8=NTWPKD^@BG@1MDX$QK,Y M3]-/<*LLB %%]C0U51+/@6U EH+@,SCD.LYYJIH61;/BK4Z.U,:->\<#%#$\ MN]E"6A)7%\+V:\NB'*O5/,=WN6K2LOTM(!F'UEI2*,OJ*A>;I7P"\]+#*_.3 M;#\GV*64OA86RY7!N_!F;%&5.5_S!BL9\SI.QH1F.4CL+!H5M\A%"S+_ MFIU]&^A"$1&'>S;5%&/C;!4=TGK'&]X3%$& N+5:(#9;&3K*'>]5M-]ZO%S8 MV%FY=3W>^A80@B*1%VX]%HC-5HZ2;NAQ9; ;^G[MN = 'HI[?MPZ;R1,6VE< M]L:&(;1Y[T &G%X+K@=$[8%:BOI#0)C2%/1-740=M,1H!&'"P?N M<5%#IK:2!:%X1['MT[^C#56C?@'-.#QB4&^S+(C85HZF/5AD.G0$^7%?:E>8 MMA)8=>,P7K%8.!H)FCWP!E]^7+;:%::M1%^(1L*S6G3/QI-():R^=)#+_9 ] M'#I0C8K=]L8[^LOXUK@0K*W<9VC.(0V$*)YF1$*4O2'MH#?>T5_&=<>%8&WE MD4,S5NQL3F] 5C1*:5#D5MS-Z6+]FT#/7\%7J%WQVFO]H'?D;)+8J^C\@QZ*&TH>?8+A;!?Z MCVC[S>CE@QZ.NSF[/(O\I*52^!%M'X$@<-PWR9GBTRN"TX5H^^:;IG8C+@]Z M..QK.YE&+(FK"_'][#F4@+G!\X5R]@E"O?9JT;5LR[ DPV16+DT2KG0C54JJ%9L-#EL;1FD"T M%'PGWP7)=\7 Q%'G'8K04BJ&O9[;WT1REJ;Y;&6;FY, QOYO<0C-A#1;/(#P MVIC/];\.C'4EB*V-.=Q4D);R.'1.]5EBJ>N$,)LT 07+=JGXO&\#6UV)>=N5 MVHO%:"G;0^>4?C517-(7.B+1R,5L7_TVL-65H+==S_7;8FRY=)2) MK#77(.5'@2 4UT0[T/,6Y=XLP/=^;QH_-YH S'/1C.J=U8 MDK;24V!WDWB"5G- ^..IA/?;_/[I#V<,K2NF 8H[#1MTM^Z\,1#'9.S7?5F! M";ZB<-A8*P?P<=P3V.53< FVC;P+CAGU)?8ND&AT'_K1G3]3)U!OXW- !@K[ M/D=#:FYW:@O!K4N)X%[I+HY^(RF[&V.]3X5IU\6% =Q^6/5J$\>YTY%(H@L> M&BLI*!:<:C$ C\,+;!?KS3;P+CR_H+U0; R2+ST4$\ V*7+RJKVW=/5O=VX6 M*#!_3"IJ $P<5XYM#D\M&;A]L\"(:N% 5-;Q^KU#!&\R*ZC09F\-E*7K7MP[ M>\>NN2!I'-;\7:SFUN1EZ4[6J69>S>9AO"#DD20O-"!\V<#V]Z6R_2TLNM6_ M,_O/79S]@V0/)(@G$?T7&55SRLNBM';Q?= &'*[GMC2/K]@[E*6MF]ENZGYY M\7$=)\M?L7*R:]K==L0[P/$XWKZ.!HE0;=WGNG^63_A4"%>,TK!"X]: U@,4 M5L26-;2^:&Q=G6+4L^*&V)::21ICHL1Q1G:B96K)V$J[W\+1.?V=9M,I"4=/ M\2-T.1TO5FX'P_$%23(X/>H^'-6\41#7<9<75&L2LI6]OJ)0._?TN !<<4A' M10C>*@)Y%5$\C4. E):I"USX>[SUB-P9>^NS5CV4&E"\9:0>@R MC@V%OGQ%D_DV+$L^#PA\"%?@2GFP22R."D<2S17%+0\R07$CI4&R;/1B-:HKCWZ>@F MNO#G-/-#);/2>B C%%XBQDQKH$*1/L 2]T&0S_+"E7>834G"!)60*9P@Z0NY MB>#P0]1ZH-L&2 _%98RY3I@AM.1XX'YF>&!A#!$97?D)2UDL=AJ45_ .3E%8 M28QYE\'I4BSZ:O>JY7.P51CD@<,!W?RO2%0VSL@L;S5N-VFV! M2''94O0'O3G,]B)0T6C-\C+9CMI(&@.!HK#06-$;)4Y;5Z.(%:<8.W?D>_$7 M^590H[YWC.0M<&O3R@8T6W>;B#6B'!4-5&*C 1 <#J=C>U/&!C9;SU)C4(J= M9?$]W4.E,,%FZT'FJF"^YG3D1^R=250SQ@Y=N8XZMKQ(@=IZB1C#O')'LM)V M>ANGLC5EK1Q(%<6]@AG?' BV7M,=D3$M/9%13 6-C$XH;@LQ4QZO.W=I_$KB2>+/IS1X)!,FF9MH'$.)(A*S3&'E MQ)>Q[,P#F<=)!I+7<5\45/$.-N()=@GC+:3Q@;R0",X&UZ"35\!5 KISD:<9 M+ A)>@8Z$$>36_I"1F=I2K)4/\E4G89!)#@LP%+*!(/2 O+N.4V^#V,_U'68 MW*P#LL%A_;7 L.+2CP^],XZ5RW%51:E.""6J [+!=;SBDR=@7(X*F8-E2H*? M)O'+YR#.HRQ9,,(/5O_#N#ZH<+W\M??K(R^NY>V/@!.'245.Q#I[F]U'YC%9 MAZ:+,PE-%V> $X579"V:5MU'Y@Y9AZ;+*PE-EU> $X?IH0Y-J^Y;\EUTO\P9 M;@]N-5R;ZC8)DL5AN6AM[]1,,IWQARS1R6XZB@+>P2$*@TX;&02#O;$:S,D]U-+J((V9](%% 2>H^;[NLT["U[JFL7_P* &%_:*&W/E#4 :S,R:L!Y:?0&&R>BL# MV%'8(F3,"+9/ZQ Z8VHJ<*F#0MY+ 7X4!HD-0B2L5?N-S&!4G[=O-**S?*9D M;JT.O6@YD@,)\HL2?=)/"<@EL?\^9\DR)[B87+VXM.037;7<3*$/_IL#KPE?JI\ M>,.T+9 EBM!-\[F^)M3.Q.P:X5>_W&'>&L@3A6-0346PH%55.=B*&FYA=5G- MI/*E9+T4@$)A'ZO-!V=AX2'$\*ZN@+:K[X#KCGS_3]:T8A_ *PL 4=B_;%(H MQFDK0K<%(L\F"2F@'O $>J<\,E;*/_MN(G+4^94]F1;K,(('%J N+)523Y:H]M13RV(/LG M*$(>LWRDV)9S"P,ZIR87OK1%C/![;RMDQ*@5!HOI?6\8QQ^ METH*C9BO8A-POU]O/#V0-$OR("O26[#'U&"S#+\CR8O2X4M>$V2T9QM1(V " M\O?0R^@)/L!"$2J@E2-?6,<[[:.XU]+BD$^_ IN ^#UT3]H:&;<:P3?B2B > M%!.^^8!781)0CL'R\Q O_#!;/, R=4^2@(E[PO/*%A>&11#%=86*!,Y>7()' M0!D&6\Z;[>F))#,:+5\YS6A RNQ22JNXH!X QWEYH292#YJ 4PR.1 \DR.B8 MEGO$X?B2C/T\S.1\RNH 8!1.O'4&I1*6@,>=NA )>+PD+R2,YTP5KW-1!B5! M20"'PG&W!FAF.G^B,I&QG!T*:WBPN2?+^(/E8ZOI92Z+:=-LP3LX MP;D3ENI(+9 "[=@O^]-!=AQ25 4IH3@/UU,%/70" M'=A#.Q@-,C*ZB5[@YT+-5=:OS?(@2YR&;BVV)9 $%#MV)WH_](&&^NET.3L- MD]OB8$BY*= U:[(GUO=UH==&)Z"U$^]],^#78?S=36K,]V>DW_IA]KKW5C7O ML.R@\U=5BY4^(/#2=B>EOYRWOPQZ*!9#'G()C,1Q+>0"<;F_L M/.-]V$-A*M;@C$^V!)6EI %.26[Z0.1A#X71L<;@W<#0F0P"=R0K-G!)_$)A M;W2^^#5EN_.W(_I9D-$7RG9TY18QA]\M_PC;(HT=AYT/@-11F#Y%^L#7'IO8 M.Y/SH%Z.M<,>BK.234:%.K,)NS/)#,Y&_\R7I_ZG^($$,1PW0[*&^"G6E*_& MU-/&Y[S#/@JGH_85L3WI(4C78$>?+PGT.* E]]'H;,8>,/B7ZG$K22V0#PJ[ M?GO<\W5-*9+.Y(38U1MZASB\Y':M2";2Z4S"B.IP&8ZO:>2#E$NG1)9[DJ6; M9'N5T;RP9 RPIKC?E)$[Y/RWXH +_PYS?Q08Q^FWPB( M#X6'6?N[*U.98$AGT9I*95.2P" F](798Q0Q0(K*("X4-B93@K75A(NW<9*, MTU(](C)AJR =#E!8 MD-I2'C'FQOE-4"M+L3#?P4$D3YCXE4_$:+;@'9Z@<'%H=3_#!]TX70IJ?3D+ MRB.CV'UV**& MOE4F)&N M;-0%<:%PQ&M+2;APNY."IYF%LS5_'Q SBON%G?AY-):3K=Q 60S#!*,ZEF$B M+;JA&7X Q([B?L**&UHM[+92$KF? 5>1AD_Q6?!G3A.R2F=]'_H1R^;"?'F+ MB&6)6NDW N)#<2]A4QGXZF8JD\:)CA =\YM)M[7Y"P2-PF#=OO+9D).U!$Q8 ME]4W_X6VEE7##WB'!RA,XE:6U5K8,22 LK2L)G% R*AXA?HF37/VR--PS%[# MC:/'+ [^D*VFJKH@+!2&3IO4"Q91/5%@R$)E=3M6<:YB]T<,Z0I^X6REWHNI M6@#!H3"%[D"'3 32./<5HET8?_!4X7AI#Y9J![<\" 6SMZ!QT,\G^"EJ!XYF&5K1"_%"#>8ZS M4BNN(K=;X,)EMY"3'ZYR65V5O]!*,*91'<2&PHIGIA'ZR 0*L8?&W)L(^D#2 M[-ZG(]B:2_V%UDJ"(% 8V?1)$_D%<6 )^,60^K^P[@V+KJ5?$Q]Z/[J.DS=# MX-)-\CR. (,P=Z51(][I*0H_L+I,UT4L4((]=#]^LPB3T67Q&$VY)2Y6N,+6 M(YON576]HR][K1Z&0 5:L8<&TK4(^[/1B):8V$1X$RT]*W^'S1 ,EE(L$BTQ M;LL[PO&>7U.MJ0E MW&4H"1O <4@#S412PDI _I$S8_52M'H&Z*W"T'441F65< 6&8@$>2]ES$8R< MQWPV\Y/%2AW6=%K ""BL(RI2!#L M?0PP6AI_+O.]7_LT*?9UWXB?PB13/M3@8)R]=82E%PICUA>=D2:KYAT>]5V- M-5Z_=(:8M!X 0F%H4 N=/[8TP.UL2/WM,^OBLY^20IS_#5!+ 0(4 Q0 ( M &B JDAN*.\7NZH $]R"P 1 " 0 !C<'AX+3(P,38P M,S,Q+GAM;%!+ 0(4 Q0 ( &B JDB1\>609 1 M " >JJ !C<'AX+3(P,38P,S,Q+GAS9%!+ 0(4 Q0 ( &B JDA-K^)^ ML@H %67 5 " 8RX !C<'AX+3(P,38P,S,Q7V-A;"YX M;6Q02P$"% ,4 " !H@*I(9F[\I%@Q S%P, %0 @ %Q MPP 8W!X>"TR,#$V,#,S,5]D968N>&UL4$L! A0#% @ :("J2-QR]A4- M30 &T0$ !4 ( !_/0 &-P>'@M,C Q-C S,S%?;&%B+GAM M;%!+ 0(4 Q0 ( &B JD@R]!Z?^S< -2[ P 5 " 3Q" M 0!C<'AX+3(P,38P,S,Q7W!R92YX;6Q02P4& 8 !@"* 0 :GH! end